var title_f30_44_31424="Malar rash";
var content_f30_44_31424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Faint malar erythema in a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Faint violaceous erythema of the cheeks and eyelids. Note the sparing of the nasolabial folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Callen, MD, FACP, FAAD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31424=[""].join("\n");
var outline_f30_44_31424=null;
var title_f30_44_31425="Herpes zoster - palate";
var content_f30_44_31425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraoral herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions are present on the palate in a unilateral distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31425=[""].join("\n");
var outline_f30_44_31425=null;
var title_f30_44_31426="WHO length for age boys 0 to 24 months";
var content_f30_44_31426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, boys birth to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 459px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31426=[""].join("\n");
var outline_f30_44_31426=null;
var title_f30_44_31427="Histoplasma from culture";
var content_f30_44_31427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Histoplasma from culture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure showing hyaline, septate hyphae, with spherical, thick-walled conidia and smaller microconidia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31427=[""].join("\n");
var outline_f30_44_31427=null;
var title_f30_44_31428="Bezafibrate: Patient drug information";
var content_f30_44_31428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bezafibrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     see \"Bezafibrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bezalip&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12704149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop irritation of the pancreas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bezafibrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Gallbladder disease, kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take during or after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11152 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31428=[""].join("\n");
var outline_f30_44_31428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12704149\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019647\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019646\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019651\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019652\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019654\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019649\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019650\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019655\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019656\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=related_link\">",
"      Bezafibrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31429="Lisdexamfetamine: Patient drug information";
var content_f30_44_31429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lisdexamfetamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/53/23382?source=see_link\">",
"     see \"Lisdexamfetamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37094?source=see_link\">",
"     see \"Lisdexamfetamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4425746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10170113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lisdexamfetamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an eating problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule into a glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12052 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31429=[""].join("\n");
var outline_f30_44_31429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10170113\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029540\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029542\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029541\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029546\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029547\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029549\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029544\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029545\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029550\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029551\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/53/23382?source=related_link\">",
"      Lisdexamfetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37094?source=related_link\">",
"      Lisdexamfetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31430="Oxygen delivery and consumption";
var content_f30_44_31430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygen delivery and consumption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Ilene M Rosen, MD, MSCE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31430/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/44/31430/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspired oxygen from the environment moves across the alveolar-capillary membrane into the blood. Most of the oxygen binds to hemoglobin in red blood cells, although a small amount dissolves into the plasma. The oxygen is then transported from the lungs to the peripheral tissues, where it is removed from the blood and used to fuel aerobic cellular metabolism. This process can be conceptualized as three steps: oxygenation, oxygen delivery, and oxygen consumption. In this topic review, oxygen delivery and consumption are reviewed. Oxygenation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oxygen content",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial oxygen content (CaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the amount of oxygen bound to hemoglobin plus the amount of oxygen dissolved in arterial blood:",
"   </p>",
"   <p>",
"    &nbsp;CaO",
"    <sub>",
"     2",
"    </sub>",
"    (mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /dL)",
"    </span>",
"    = (1.34 x hemoglobin concentration x SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) + (0.0031 x PaO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"   </p>",
"   <p>",
"    where SaO",
"    <sub>",
"     2",
"    </sub>",
"    is the arterial oxyhemoglobin saturation and PaO",
"    <sub>",
"     2",
"    </sub>",
"    is the arterial oxygen tension. Normal CaO",
"    <sub>",
"     2",
"    </sub>",
"    is approximately 20 mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /dL.",
"    </span>",
"   </p>",
"   <p>",
"    Similarly, the mixed venous blood oxygen content (CvO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the amount of oxygen bound to hemoglobin plus the amount of oxygen dissolved in mixed venous blood:",
"   </p>",
"   <p>",
"    &nbsp;CvO",
"    <sub>",
"     2",
"    </sub>",
"    (mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /dL)",
"    </span>",
"    = (1.34 x hemoglobin concentration x SvO",
"    <sub>",
"     2",
"    </sub>",
"    ) + (0.0031 x PvO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"   </p>",
"   <p>",
"    where SvO",
"    <sub>",
"     2",
"    </sub>",
"    is the mixed venous oxyhemoglobin saturation and PvO",
"    <sub>",
"     2",
"    </sub>",
"    is the mixed venous oxygen tension. Normal CvO",
"    <sub>",
"     2",
"    </sub>",
"    is approximately 15 mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /dL.",
"    </span>",
"    Mixed venous blood is drawn from the right atrium. Peripheral venous blood should not be substituted because it tends to overestimate venous oxygen content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen delivery (DO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the rate at which oxygen is transported from the lungs to the microcirculation:",
"   </p>",
"   <p>",
"    &nbsp;DO",
"    <sub>",
"     2",
"    </sub>",
"    <span class=\"nowrap\">",
"     (mL/min)",
"    </span>",
"    = Q x CaO",
"    <sub>",
"     2",
"    </sub>",
"   </p>",
"   <p>",
"    where Q is the cardiac output. Normal DO",
"    <sub>",
"     2",
"    </sub>",
"    is approximately 1000",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Normal DO",
"    <sub>",
"     2",
"    </sub>",
"    is approximately 500",
"    <span class=\"nowrap\">",
"     mL/min/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if cardiac index is substituted for cardiac output.",
"   </p>",
"   <p>",
"    Realize, cardiac output can be measured by thermodilution using a pulmonary artery catheter, or calculated using the Fick equation:",
"   </p>",
"   <p>",
"    &nbsp;Q",
"    <span class=\"nowrap\">",
"     (L/min)",
"    </span>",
"    = Oxygen consumption &divide; (10 x arteriovenous oxygen difference)",
"   </p>",
"   <p>",
"    where oxygen consumption is either measured by respirometry (discussed below) or estimated using a nomogram, and the arteriovenous (AV) oxygen difference is calculated:",
"   </p>",
"   <p>",
"    &nbsp;AV oxygen difference (mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /dL)",
"    </span>",
"    = CaO",
"    <sub>",
"     2",
"    </sub>",
"    - CvO",
"    <sub>",
"     2",
"    </sub>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oxygen consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the rate at which oxygen is removed from the blood for use by the tissues. It can be measured directly or calculated. Both approaches assume that all unused oxygen passes from the arterial to the venous circulation.",
"   </p>",
"   <p>",
"    Direct measurement of VO",
"    <sub>",
"     2",
"    </sub>",
"    is performed by respirometry. During respirometry, the patient breathes through a chamber that receives continuous air flow. Measurement of the oxygen depleted from the chamber, as well as the carbon dioxide and water vapor produced in the chamber, is used to determine VO",
"    <sub>",
"     2",
"    </sub>",
"    . Respirometry can be used in mechanically ventilated patients, but the accuracy of direct measurement of VO",
"    <sub>",
"     2",
"    </sub>",
"    diminishes at high oxygen concentrations (eg, &gt;80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Normal VO",
"    <sub>",
"     2",
"    </sub>",
"    in a conscious, resting person is approximately 250 mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /min.",
"    </span>",
"   </p>",
"   <p>",
"    Calculation of VO",
"    <sub>",
"     2",
"    </sub>",
"    can be performed by rearranging the Fick equation:",
"   </p>",
"   <p>",
"    &nbsp;VO",
"    <sub>",
"     2",
"    </sub>",
"    (mL",
"    <span class=\"nowrap\">",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     /min)",
"    </span>",
"    = Q x (CaO",
"    <sub>",
"     2",
"    </sub>",
"    - CvO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"   </p>",
"   <p>",
"    When calculating VO",
"    <sub>",
"     2",
"    </sub>",
"    , cardiac output should be measured and not calculated from the Fick equation or a mathematical coupling error may be introduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxygen extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen extraction is the slope of the relationship between oxygen delivery (DO",
"    <sub>",
"     2",
"    </sub>",
"    ) and oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    ). It is most commonly expressed as the oxygen extraction ratio, which is the proportion of arterial oxygen that is removed from the blood as it passes through the microcirculation:",
"   </p>",
"   <p>",
"    &nbsp;O",
"    <sub>",
"     2",
"    </sub>",
"    Extraction Ratio = (CaO",
"    <sub>",
"     2",
"    </sub>",
"    -",
"    <span class=\"nowrap\">",
"     CvO",
"     <sub>",
"      2",
"     </sub>",
"     )/CaO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"   </p>",
"   <p>",
"    Normal O",
"    <sub>",
"     2",
"    </sub>",
"    extraction ratios range from 0.25 to 0.30.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NORMAL PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal circumstances,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen consumption (VO",
"      <sub>",
"       2",
"      </sub>",
"      ) is proportional to oxygen delivery (DO",
"      <sub>",
"       2",
"      </sub>",
"      ) and oxygen extraction",
"     </li>",
"     <li>",
"      DO",
"      <sub>",
"       2",
"      </sub>",
"      and oxygen extraction are inversely proportional to one another",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At rest, VO",
"    <sub>",
"     2",
"    </sub>",
"    remains constant over a wide range of oxygen delivery (DO",
"    <sub>",
"     2",
"    </sub>",
"    ) because changes in DO",
"    <sub>",
"     2",
"    </sub>",
"    are balanced by reciprocal changes in oxygen extraction (",
"    <a class=\"graphic graphic_figure graphicRef52578 \" href=\"mobipreview.htm?6/15/6398\">",
"     figure 1",
"    </a>",
"    ). VO",
"    <sub>",
"     2",
"    </sub>",
"    decreases if DO",
"    <sub>",
"     2",
"    </sub>",
"    declines to such a degree that it cannot be balanced by increasing oxygen extraction. The threshold value of DO",
"    <sub>",
"     2",
"    </sub>",
"    below which VO",
"    <sub>",
"     2",
"    </sub>",
"    will fall is called the \"critical DO",
"    <sub>",
"     2",
"    </sub>",
"    \" (",
"    <a class=\"graphic graphic_figure graphicRef54410 \" href=\"mobipreview.htm?4/63/5118\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When metabolic demand increases (eg, exercise, pregnancy), VO",
"    <sub>",
"     2",
"    </sub>",
"    also increases because more oxygen is required to maintain aerobic cellular metabolism. This is normally achieved by increasing both DO",
"    <sub>",
"     2",
"    </sub>",
"    and oxygen extraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. VO",
"    <sub>",
"     2",
"    </sub>",
"    is disproportionately impacted by the increased oxygen extraction, with the increased DO",
"    <sub>",
"     2",
"    </sub>",
"    contributing little [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/9\">",
"     9",
"    </a>",
"    ]. Enhanced extraction of oxygen is probably mediated at the capillary level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased oxygen delivery or increased metabolic demand are common sequelae of medical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Decreased oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen delivery (DO",
"    <sub>",
"     2",
"    </sub>",
"    ) will decrease if cardiac output falls or arterial oxygen content (CaO",
"    <sub>",
"     2",
"    </sub>",
"    ) declines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac output can decrease due to cardiac disease or hypovolemia.",
"     </li>",
"     <li>",
"      CaO",
"      <sub>",
"       2",
"      </sub>",
"      can decrease due to anemia or poor oxygenation. The latter can be caused by lung disease (eg, ventilation-perfusion mismatch, diffusion limitation), a right-to-left shunt, diminished inspired oxygen, or hypoventilation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=see_link\">",
"       \"Oxygenation and mechanisms of hypoxemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of diminished DO",
"    <sub>",
"     2",
"    </sub>",
"    , maintenance of a normal VO",
"    <sub>",
"     2",
"    </sub>",
"    can be accomplished by a compensatory increase in oxygen extraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/10\">",
"     10",
"    </a>",
"    ]. If increased oxygen extraction is insufficient to maintain VO",
"    <sub>",
"     2",
"    </sub>",
"    , cardiac output will increase in an effort to improve DO",
"    <sub>",
"     2",
"    </sub>",
"    . VO",
"    <sub>",
"     2",
"    </sub>",
"    will fall if these actions are insufficient and DO",
"    <sub>",
"     2",
"    </sub>",
"    is below the critical DO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Increased metabolic demand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic demand is elevated in critically ill patients (eg, acute respiratory distress syndrome, sepsis, or septic shock) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/2,5,12-19\">",
"     2,5,12-19",
"    </a>",
"    ]. VO",
"    <sub>",
"     2",
"    </sub>",
"    increases because more oxygen is required to maintain aerobic cellular metabolism. In critically ill patients, VO",
"    <sub>",
"     2",
"    </sub>",
"    elevation may be disproportionately accomplished by increasing the DO",
"    <sub>",
"     2",
"    </sub>",
"    . This is different from healthy individuals in whom VO",
"    <sub>",
"     2",
"    </sub>",
"    elevation is disproportionately accomplished by increasing the oxygen extraction, with DO",
"    <sub>",
"     2",
"    </sub>",
"    contributing little [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/9\">",
"     9",
"    </a>",
"    ]. Whether such a difference exists between healthy and critically ill individuals is controversial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proponents believe that VO",
"      <sub>",
"       2",
"      </sub>",
"      is disproportionately affected by DO",
"      <sub>",
"       2",
"      </sub>",
"      because oxygen extraction is impaired during critical illness. Supporting this hypothesis, lactic acidosis is often present despite increased DO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In other words, anaerobic metabolism is required despite an increased supply of oxygen. Ineffective oxygen extraction may be due to poor oxygen uptake or poor utilization by the cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Opponents argue that both VO",
"      <sub>",
"       2",
"      </sub>",
"      and DO",
"      <sub>",
"       2",
"      </sub>",
"      were calculated in most of the studies that suggest that DO",
"      <sub>",
"       2",
"      </sub>",
"      has a disproportionate impact on VO",
"      <sub>",
"       2",
"      </sub>",
"      during critical illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/22\">",
"       22",
"      </a>",
"      ]. This could introduce mathematical coupling errors, which would falsely increase the strength of the relationship between VO",
"      <sub>",
"       2",
"      </sub>",
"      and DO",
"      <sub>",
"       2",
"      </sub>",
"      . In addition, VO",
"      <sub>",
"       2",
"      </sub>",
"      was not disproportionately affected by DO",
"      <sub>",
"       2",
"      </sub>",
"      in the few studies that directly measured VO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/2,23-26\">",
"       2,23-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We believe that the relationship between DO",
"    <sub>",
"     2",
"    </sub>",
"    and VO",
"    <sub>",
"     2",
"    </sub>",
"    in critically ill patients is similar to that in healthy patients during increased metabolic demand (eg, exercise, pregnancy). In other words, we believe that increased oxygen extraction, and not increased DO",
"    <sub>",
"     2",
"    </sub>",
"    , has the greatest impact on increasing the VO",
"    <sub>",
"     2",
"    </sub>",
"    in critically ill patients. We base this belief on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous studies have evaluated the impact of augmenting DO",
"      <sub>",
"       2",
"      </sub>",
"      on VO",
"      <sub>",
"       2",
"      </sub>",
"      with conflicting results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/2,6,8,23-42\">",
"       2,6,8,23-42",
"      </a>",
"      ]. Methods of augmenting DO",
"      <sub>",
"       2",
"      </sub>",
"      have included inotropic agents, saline loading, and vasodilators to improve cardiac output, as well as red blood cell transfusions to increase arterial oxygen content (CaO",
"      <sub>",
"       2",
"      </sub>",
"      ). Regardless of the intervention, DO",
"      <sub>",
"       2",
"      </sub>",
"      and VO",
"      <sub>",
"       2",
"      </sub>",
"      were strongly correlated when VO",
"      <sub>",
"       2",
"      </sub>",
"      and DO",
"      <sub>",
"       2",
"      </sub>",
"      were both calculated, but not when VO",
"      <sub>",
"       2",
"      </sub>",
"      was directly measured.",
"     </li>",
"     <li>",
"      A few studies have evaluated the impact of augmenting DO",
"      <sub>",
"       2",
"      </sub>",
"      and patient-centered outcomes, such as survival, organ failure, length of ICU stay, and length of hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31430/abstract/33,35-37,43-49\">",
"       33,35-37,43-49",
"      </a>",
"      ]. While some of the studies found an improvement in morbidity or mortality, others found no effect or potential harm. Those that demonstrated improvement had significant methodologic problems, such as baseline differences between the treatment and control groups, and failure to use an intention-to-treat analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, we believe there are insufficient data to warrant the routine augmentation of DO",
"    <sub>",
"     2",
"    </sub>",
"    in critically ill patients if there is no evidence of ongoing tissue hypoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspired oxygen from the environment moves across the alveolar-capillary membrane into the blood and is then transported to the peripheral tissues. There, it is removed from the blood and used to fuel aerobic cellular metabolism. This process can be conceptualized as three steps: oxygenation, oxygen delivery, and oxygen consumption. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The arterial oxygen content (CaO",
"      <sub>",
"       2",
"      </sub>",
"      ) is the amount of oxygen bound to hemoglobin plus the amount of oxygen dissolved in arterial blood, while the mixed venous blood oxygen content (CvO",
"      <sub>",
"       2",
"      </sub>",
"      ) is the amount of oxygen bound to hemoglobin plus the amount of oxygen dissolved in mixed venous blood. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oxygen content'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oxygen delivery (DO",
"      <sub>",
"       2",
"      </sub>",
"      ) is the rate at which oxygen is transported from the lungs to the microcirculation, oxygen consumption (VO",
"      <sub>",
"       2",
"      </sub>",
"      ) is the rate at which oxygen is removed from the blood for use by the tissues, and oxygen extraction is the proportion of arterial oxygen that is removed from the blood as it passes through the microcirculation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Oxygen delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Oxygen consumption'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Oxygen extraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VO",
"      <sub>",
"       2",
"      </sub>",
"      normally remains constant over a wide range of DO",
"      <sub>",
"       2",
"      </sub>",
"      because changes in DO",
"      <sub>",
"       2",
"      </sub>",
"      are balanced by reciprocal changes in oxygen extraction. VO",
"      <sub>",
"       2",
"      </sub>",
"      will decrease only if DO",
"      <sub>",
"       2",
"      </sub>",
"      declines to such a degree that it cannot be balanced by increasing oxygen extraction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Normal physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VO",
"      <sub>",
"       2",
"      </sub>",
"      increases when metabolic demand increases (eg, exercise, pregnancy). This is disproportionately accomplished by increasing the oxygen extraction, with DO",
"      <sub>",
"       2",
"      </sub>",
"      contributing little. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Normal physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased oxygen delivery or increased metabolic demand are common sequelae of medical illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When DO",
"      <sub>",
"       2",
"      </sub>",
"      is decreased (eg, heart failure), a compensatory increase in oxygen extraction may allow VO",
"      <sub>",
"       2",
"      </sub>",
"      to remain normal. If increased oxygen extraction is insufficient to maintain VO",
"      <sub>",
"       2",
"      </sub>",
"      , cardiac output will increase in an effort to improve DO",
"      <sub>",
"       2",
"      </sub>",
"      . VO",
"      <sub>",
"       2",
"      </sub>",
"      will fall if these compensatory mechanisms are inadequate. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Decreased oxygen delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When metabolic demand increases (eg, sepsis), VO",
"      <sub>",
"       2",
"      </sub>",
"      also increases. This may be disproportionately accomplished by increasing the DO",
"      <sub>",
"       2",
"      </sub>",
"      , rather than enhancing the oxygen extraction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Increased metabolic demand'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In critically ill patients in whom there is no evidence of ongoing tissue hypoxia, we suggest that DO",
"      <sub>",
"       2",
"      </sub>",
"      should NOT be routinely augmented (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Increased metabolic demand'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/1\">",
"      Feenstra BW, Holland WP, van Lanschot JJ, Bruining HA. Design and validation of an automatic metabolic monitor. Intensive Care Med 1985; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/2\">",
"      Vermeij CG, Feenstra BW, Adrichem WJ, Bruining HA. Independent oxygen uptake and oxygen delivery in septic and postoperative patients. Chest 1991; 99:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/3\">",
"      Mira JP, Fabre JE, Baigorri F, et al. Lack of oxygen supply dependency in patients with severe sepsis. A study of oxygen delivery increased by military antishock trouser and dobutamine. Chest 1994; 106:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/4\">",
"      Shepherd AP, Granger HJ, Smith EE, Guyton AC. Local control of tissue oxygen delivery and its contribution to the regulation of cardiac output. Am J Physiol 1973; 225:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/5\">",
"      Dantzker DR, Foresman B, Gutierrez G. Oxygen supply and utilization relationships. A reevaluation. Am Rev Respir Dis 1991; 143:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/6\">",
"      Dantzker D. Oxygen delivery and utilization in sepsis. Crit Care Clin 1989; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/7\">",
"      Cain SM. Acute lung injury. Assessment of tissue oxygenation. Crit Care Clin 1986; 2:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/8\">",
"      Kruse JA, Haupt MT, Puri VK, Carlson RW. Lactate levels as predictors of the relationship between oxygen delivery and consumption in ARDS. Chest 1990; 98:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/9\">",
"      Chiol&eacute;ro R, Flatt JP, Revelly JP, J&eacute;quier E. Effects of catecholamines on oxygen consumption and oxygen delivery in critically ill patients. Chest 1991; 100:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/10\">",
"      Cain SM. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977; 42:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/11\">",
"      Shibutani K, Komatsu T, Kubal K, et al. Critical level of oxygen delivery in anesthetized man. Crit Care Med 1983; 11:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/12\">",
"      Wysocki M, Besbes M, Roupie E, Brun-Buisson C. Modification of oxygen extraction ratio by change in oxygen transport in septic shock. Chest 1992; 102:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/13\">",
"      Silverman HJ. Lack of a relationship between induced changes in oxygen consumption and changes in lactate levels. Chest 1991; 100:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/14\">",
"      Annat G, Viale JP, Percival C, et al. Oxygen delivery and uptake in the adult respiratory distress syndrome. Lack of relationship when measured independently in patients with normal blood lactate concentrations. Am Rev Respir Dis 1986; 133:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/15\">",
"      Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest 1992; 102:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/16\">",
"      Vermeij CG, Feenstra BW, Bruining HA. Oxygen delivery and oxygen uptake in postoperative and septic patients. Chest 1990; 98:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/17\">",
"      Russell JA, Ronco JJ, Lockhat D, et al. Oxygen delivery and consumption and ventricular preload are greater in survivors than in nonsurvivors of the adult respiratory distress syndrome. Am Rev Respir Dis 1990; 141:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/18\">",
"      Danek SJ, Lynch JP, Weg JG, Dantzker DR. The dependence of oxygen uptake on oxygen delivery in the adult respiratory distress syndrome. Am Rev Respir Dis 1980; 122:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/19\">",
"      Mohsenifar Z, Goldbach P, Tashkin DP, Campisi DJ. Relationship between O2 delivery and O2 consumption in the adult respiratory distress syndrome. Chest 1983; 84:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/20\">",
"      Kariman K, Burns SR. Regulation of tissue oxygen extraction is disturbed in adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/21\">",
"      Ronco JJ, Montaner JS, Fenwick JC, et al. Pathologic dependence of oxygen consumption on oxygen delivery in acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest 1990; 98:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/22\">",
"      Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med 1994; 149:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/23\">",
"      Ronco JJ, Phang PT, Walley KR, et al. Oxygen consumption is independent of changes in oxygen delivery in severe adult respiratory distress syndrome. Am Rev Respir Dis 1991; 143:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/24\">",
"      Villar J, Slutsky AS, Hew E, Aberman A. Oxygen transport and oxygen consumption in critically ill patients. Chest 1990; 98:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/25\">",
"      Weissman C, Kemper M. The oxygen uptake-oxygen delivery relationship during ICU interventions. Chest 1991; 99:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/26\">",
"      Boyd O, Grounds M, Bennett D. The dependency of oxygen consumption on oxygen delivery in critically ill postoperative patients is mimicked by variations in sedation. Chest 1992; 101:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/27\">",
"      Majerus TC, Chodoff P, Borel CO. Dopamine and dobutamine in septic shock. A comparison. Arch Int Physiol Biochim 1984; 92:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/28\">",
"      Gilbert EM, Haupt MT, Mandanas RY, et al. The effect of fluid loading, blood transfusion, and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respir Dis 1986; 134:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/29\">",
"      Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport effects of dobutamine in critically ill general surgical patients. Crit Care Med 1986; 14:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/30\">",
"      Shoemaker WC, Appel PL, Kram HB, et al. Comparison of hemodynamic and oxygen transport effects of dopamine and dobutamine in critically ill surgical patients. Chest 1989; 96:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/31\">",
"      Vincent JL, Roman A, Kahn RJ. Dobutamine administration in septic shock: addition to a standard protocol. Crit Care Med 1990; 18:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/32\">",
"      Vincent JL, Roman A, De Backer D, Kahn RJ. Oxygen uptake/supply dependency. Effects of short-term dobutamine infusion. Am Rev Respir Dis 1990; 142:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/33\">",
"      Lobo SM, Salgado PF, Castillo VG, et al. Effects of maximizing oxygen delivery on morbidity and mortality in high-risk surgical patients. Crit Care Med 2000; 28:3396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/34\">",
"      Ronco JJ, Fenwick JC, Wiggs BR, et al. Oxygen consumption is independent of increases in oxygen delivery by dobutamine in septic patients who have normal or increased plasma lactate. Am Rev Respir Dis 1993; 147:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/35\">",
"      Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/36\">",
"      Al&iacute;a I, Esteban A, Gordo F, et al. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock. Chest 1999; 115:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/37\">",
"      Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/38\">",
"      Bollaert PE, Bauer P, Audibert G, et al. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 1990; 98:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/39\">",
"      Kaufman BS, Rackow EC, Falk JL. The relationship between oxygen delivery and consumption during fluid resuscitation of hypovolemic and septic shock. Chest 1984; 85:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/40\">",
"      Bihari D, Smithies M, Gimson A, Tinker J. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 1987; 317:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/41\">",
"      Pittet JF, Lacroix JS, Gunning K, et al. Prostacyclin but not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure. Chest 1990; 98:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/42\">",
"      Silverman HJ, Slotman G, Bone RC, et al. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial. The Prostaglandin E1 Study Group. Chest 1990; 98:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/43\">",
"      Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/44\">",
"      Edwards JD, Brown GC, Nightingale P, et al. Use of survivors' cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med 1989; 17:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/45\">",
"      Yu M, Levy MM, Smith P, et al. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med 1993; 21:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/46\">",
"      Bishop MH, Shoemaker WC, Appel PL, et al. Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma. J Trauma 1995; 38:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/47\">",
"      Hinds C, Watson D. Manipulating hemodynamics and oxygen transport in critically ill patients. N Engl J Med 1995; 333:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/48\">",
"      Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31430/abstract/49\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1623 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31430=[""].join("\n");
var outline_f30_44_31430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oxygen content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oxygen consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxygen extraction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NORMAL PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Decreased oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Increased metabolic demand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1623|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/15/6398\" title=\"figure 1\">",
"      Extraction ratios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/63/5118\" title=\"figure 2\">",
"      VO2 DO2 relationships",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31431="Principles of snake bite management worldwide";
var content_f30_44_31431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of snake bite management worldwide",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Allen C Cheng, MB, BS, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31431/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/44/31431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snake bites account for approximately 125,000 deaths annually worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/1\">",
"     1",
"    </a>",
"    ]. The venom from four families of snakes (Atractaspididae, Colubridae, Elapidae, and Viperidae) is toxic to humans. In the United States, snake bites are less common and the types of poisonous snakes differ. The principles of management of snake bites within the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=see_link\">",
"     \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modes of action of snake venom must be understood in order to consider appropriate management. Snake venom varies in potency and action, but several syndromes can be distinguished following envenomation (",
"    <a class=\"graphic graphic_table graphicRef73959 \" href=\"mobipreview.htm?15/19/15676\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurotoxicity",
"     </li>",
"     <li>",
"      Systemic toxicity including hypotension and shock",
"     </li>",
"     <li>",
"      Coagulopathy",
"     </li>",
"     <li>",
"      Rhabdomyolysis",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Local tissue necrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major aspects of snake bite treatment include field management, hospital assessment, and hospital management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIELD MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial first aid of envenomation is directed at reducing the spread of venom and expediting transfer to an appropriate medical center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general principles are agreed upon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be removed from the snake's territory, kept warm and at rest, and be reassured.",
"     </li>",
"     <li>",
"      The injured part of the body should be immobilized in a functional position below the level of the heart.",
"     </li>",
"     <li>",
"      The wound should be cleansed, except in areas in which a venom detection kit is used (ie, Australia).",
"     </li>",
"     <li>",
"      Withhold alcohol and drugs that may confound clinical assessment.",
"     </li>",
"     <li>",
"      Attempt to identify the snake, without endangering the patient or rescuer. A digital photo taken at a safe distance may be useful. Snake parts should not be handled directly. The bite reflex may remain intact in recently killed snakes, possibly being able to inflict a bite [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transport the patient to the nearest medical facility as quickly as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pressure immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pressure immobilization technique to delay systemic absorption of snake venom has widespread use in Australia, where elapid toxin primarily causes neurotoxicity without tissue necrosis and where there may be significant delays in transfer to medical facilities (",
"    <a class=\"graphic graphic_figure graphicRef68766 \" href=\"mobipreview.htm?35/62/36842\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/3\">",
"     3",
"    </a>",
"    ]. Its efficacy was first demonstrated in studies on monkeys using tiger snake venom (Notechis scutatus) with high systemic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/5\">",
"     5",
"    </a>",
"    ]. Immobilization of the envenomed limb and application of pressure of 55 mmHg resulted in a significant delay in systemic absorption of venom. Dramatic benefits have also been described in anecdotal reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the value of pressure immobilization against venoms is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/3\">",
"     3",
"    </a>",
"    ]. Some venoms, such as cobra and viper venom, primarily produce local necrosis; in this setting, localization of toxin may worsen the syndrome. Other potential problems with this technique include the availability of suitable materials and difficulty in determining the appropriate pressure to apply. If the compression bandage is too loose, it will fail to work, and if too tight, it may obstruct arterial flow.",
"   </p>",
"   <p>",
"    Another concern is that release of the compression bandage may result in sudden systemic envenomation. Thus, compression bandages, if used, should not be removed until the patient has reached the hospital and a clinical assessment of the patient has occurred.",
"   </p>",
"   <p>",
"    The pressure immobilization technique is generally recommended following envenomation by snakes with neurotoxic venom, including Australian elapids. It is usually not advised following bites from snakes with locally necrotic venom, such as cobras and vipers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methods not recommended",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods such as incision and oral suction, mechanical suction devices, cryotherapy, surgery, and electric shock therapy have been widely used, but are no longer recommended. As an example, a common misconception is that one should apply a tourniquet, suck out the poison, and spit it out. However, this approach is strongly discouraged, since it can damage nerves, tendons, and blood vessels and lead to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. Furthermore, venom removal by suction is minimal. This was illustrated in a study of mock venom extraction with a mechanical suction device in human volunteers; suction reduced the total body venom burden by only two percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HOSPITAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the effects of snake venom can be divided into distinct syndromes, which may vary in severity depending upon the species of snake (",
"    <a class=\"graphic graphic_table graphicRef73959 \" href=\"mobipreview.htm?15/19/15676\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/3\">",
"     3",
"    </a>",
"    ]. The evaluation of the patient should take into account each syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation of the bite",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable variation in the locally necrotic action of snake venom. In Australia, since little local necrosis and minimal local pain are common, fang marks may easily be missed. In contrast, cobras and vipers may cause extensive local tissue destruction.",
"   </p>",
"   <p>",
"    The first clinical indications of systemic envenomation are often nonspecific symptoms such as nausea, vomiting, abdominal pain, and headache. The presence of these symptoms should prompt an intensive assessment for the other clinical syndromes associated with snake envenomation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venoms of the elapids of the Australia-Pacific region are associated with severe neurotoxicity. Neurotoxicity is characterized initially by ptosis, diplopia, and bulbar palsy with onset between 1 to 10 hours following envenomation. Symptoms can later progress to dysarthria and more generalized weakness. As a result, frequent, serial observations for ptosis, diplopia, and impaired swallowing function are of paramount importance. Ventilatory support may be required for airway protection or respiratory paralysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom may be either a procoagulant or an anticoagulant, but both produce similar coagulation disorders rapidly. Signs of overt bleeding should be sought following a snake bite. Low-grade bleeding from gums and epistaxis are common. Stroke resulting primarily from intracranial hemorrhage complicated Bothrops spp snake bites in 2.6 percent of cases in a series from Ecuador [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/11\">",
"     11",
"    </a>",
"    ] and is a well-recognized complication following Australian elapid and certain other bites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The whole blood clotting test (WBCT) is a useful bedside screening test; failure of the blood to clot in a clean glass tube after 20 minutes is evidence of severe hypofibrinogenemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/14\">",
"     14",
"    </a>",
"    ]. Where available, coagulation parameters such as INR, aPTT, fibrinogen, and fibrin degradation products should be taken at baseline.",
"   </p>",
"   <p>",
"    The optimal management of asymptomatic patients with laboratory evidence of coagulation defects is uncertain. Extrapolation from other settings has led to the suggestion that a multicomponent coagulopathy with parameters exceeding critical thresholds (INR &gt;3.0, aPTT &gt;50 seconds, platelets",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL,",
"    </span>",
"    and fibrinogen &lt;75",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is associated with a major bleeding risk of 1 percent over a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical assessment, the WBCT and other clotting parameters should be followed serially. The presence of coagulopathy may be useful in the clinical diagnosis of snake bite. In Papua New Guinea, for example, envenomation from the death adder rarely causes a significant coagulopathy in contrast to that of the taipan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypotension and shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension and shock may result from a snake bite. The mechanisms for these findings include: vasodilation, a direct action of venom on the myocardium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypovolemia due to bleeding. Following a snake bite, assessment of fluid status clinically, or where available, with central monitoring is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of muscle pain, weakness, and dark urine is suggestive that massive rhabdomyolysis has occurred. Creatine kinase and electrolytes, particularly hyperkalemia, should be followed serially, and the presence of myoglobinuria should be documented. Urine dipstick tests for the presence of blood detect both myoglobin and hemoglobin (as well as hematuria) and positive results are suggestive of significant rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure following a snake bite may be multifactorial resulting from hypotension, rhabdomyolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated intravascular coagulation (DIC). In a prospective observational study of 100 patients envenomed with Crotalus durissus, 29 patients developed acute renal failure (ARF) due to rhabdomyolysis. Independent risk factors for ARF included age less than 12 years (odds ratio [OR] 5.6, 95% CI 1.2-26.2), a delay in antivenom therapy of &gt;2 hours (OR 11.1, 95% CI 1.2-101), and a creatinine kinase at admission &gt;2000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (OR 12.7, 95% CI 2.8-58) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, diuresis at admission &gt;90 mL per hour (OR 0.2, 95% CI 0.05-0.7) was protective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of snake bites do not result in envenomation; thus, patients without clinical features of local or systemic envenomation should be closely observed before discharge from medical attention. The time required for observation in hospital before discharge of an asymptomatic patient with possible envenomation is a local issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/17\">",
"     17",
"    </a>",
"    ]. Each hospital where admissions for snake bites occur should assess and prospectively evaluate its own discharge criteria based upon the venom properties of the local snake fauna and the level of clinical and laboratory expertise available.",
"   </p>",
"   <p>",
"    Oxygen should not routinely be administered to patients with suspected neurotoxic envenomation. Although the other clinical features of neurotoxicity usually manifest earlier (particularly bulbar palsy), hypoxia due to hypoventilation mandates intubation. Detection of hypoxia would be impaired by oxygen therapy. The need for tetanus toxoid should be assessed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine use of antibiotics is controversial and depends in part upon the local rates of infection. Many authorities do not advocate treatment unless an established infection is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/2\">",
"     2",
"    </a>",
"    ]. Local practices vary; for example, infections are thought to be more common in Brazil, occurring in up to 10 percent of cases of snake bite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/18\">",
"     18",
"    </a>",
"    ]. However, a double-blind randomized controlled trial in 251 patients following Bothrops envenomation in Brazil, found that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    (500 mg every six hours for five days) did not prevent abscess formation (4.9 percent developed abscess in the chloramphenicol group compared with 4.7 percent in the placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/19\">",
"     19",
"    </a>",
"    ]. Similarly, a study in 144 patients from Sri Lanka found no significant difference in swelling in patients randomly assigned to benzylpenicillin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Where possible, the snake should be identified clinically, by examination or by venom kit testing. Local knowledge is vital in this regard; in Southeast Asia, for example, syndromic diagnosis has been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/21\">",
"     21",
"    </a>",
"    ]. In Australia, snakes may vary widely in appearance, and identification is rarely possible by the clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/22\">",
"     22",
"    </a>",
"    ]; however, venom detection kits are useful in determining the appropriate monovalent antivenom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. If there is doubt about the identity of the snake, treatment should be administered for an unidentified snake bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antivenom",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antivenom depends upon availability and the risk-benefit ratio; thus, this is a clinical decision, which must be made for each patient on an individual basis. Any decision to use antivenom must take into account the association of most antivenoms with a high incidence of allergic reactions. Antivenoms are generally indicated when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence of systemic envenomation (neurotoxicity, coagulopathy, rhabdomyolysis, persistent hypotension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal failure).",
"     </li>",
"     <li>",
"      There is severe local envenomation, manifested by local tissue destruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although delays in administration result in lowered effectiveness, anecdotal evidence suggests that some improvement is possible even days after envenomation with some snakes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preparation, dosing, and administration of antivenom should follow established local product information guidelines; dosing is generally the same for children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to most antivenom are common and may be divided into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early allergic reactions",
"     </li>",
"     <li>",
"      Pyrogenic reactions",
"     </li>",
"     <li>",
"      Late allergic reactions (serum sickness)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of early and late allergic reactions varies with different antivenom preparations and depends on the method of purification, the total foreign protein load and the composition of the antivenom (whole immunoglobulin compared with Fab fragments) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of prophylactic epinephrine prior to the administration of antivenoms known to have high rates of allergic reactions is controversial. A randomized, placebo-controlled trial of 105 Sri Lankan patients demonstrated a significant reduction in adverse events due to the antivenom, with no reported adverse events ascribed to the use of epinephrine (0.25 mL of an 0.1 percent [1:1000] solution subcutaneously) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/27\">",
"     27",
"    </a>",
"    ]. In another trial of 52 patients from the same center, the frequency of mild-to-moderate early reactions was reduced with the combination of an antihistamine bolus and a corticosteroid infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the rate of acute reactions to the polyvalent antivenom in the control arm in both studies was extremely high (&gt;40 percent). As a result, these benefits should be interpreted with caution in other regions.",
"   </p>",
"   <p>",
"    Prophylactic antihistamines alone were not beneficial in the Brazilian study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/29\">",
"     29",
"    </a>",
"    ]. Corticosteroids are often used with early and late allergic reactions.",
"   </p>",
"   <p>",
"    Although definitive data are lacking, we feel that premedication with epinephrine is appropriate in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In areas in which use of antivenom is associated with high rates of allergic reactions.",
"     </li>",
"     <li>",
"      In settings in which there is an appreciable risk of allergic reaction associated with antivenom use and the management of acute allergic reactions is problematic because of limited staffing or facilities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If premedication is not given, epinephrine (0.5 to 1 mL of an 0.1 percent [1:1000] solution) should be prepared prior to the administration of any antivenom in the event that it is needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Failure to respond",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of response to antivenom may be due to the wrong monovalent antivenom, insufficient antivenom, inactive antivenom or an excessive delay in administration after envenomation. Expired antivenom, sometimes used by veterinarians, may retain its potency for some time following its use-by date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk-benefit ratio may still support its use if no \"in date\" antivenom is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specific management of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific management of all complications is the administration of adequate amounts of antivenom. The following points may be useful when considering specific syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Local",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compartment syndromes may be confused with the appearance of local necrosis following envenomation but are rare. Fasciotomies should only be performed following confirmation of raised intracompartmental pressure with a Stryker needle (Stryker Instruments, Kalamazoo, MI) or intravenous cannula and pressure transducer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/32\">",
"     32",
"    </a>",
"    ] and the correction of coagulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of response in neuropathic symptoms appears to depend upon the timing of administration of antivenom. Intubation and ventilation are required for airway protection or respiratory support if bulbar palsy, increasing dyspnea, or respiratory failure is present.",
"   </p>",
"   <p>",
"    Postsynaptic neurotoxins, which are present in venom of the death adder (Acanthophis spp) and the Philippine cobra (Naja philippinensis), may be fully or partially reversed by an anticholinesterase such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    (10 mg in adults) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    (50 to 100 mcg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This may be particularly useful in settings where antivenom is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not possible to correct coagulation defects without sufficient antivenom; as a result, persisting bleeding should prompt the administration of additional antivenom. Clotting factor replacement with whole blood or fresh frozen plasma is only indicated in cases of life-threatening hemorrhage after the use of antivenom. Although spontaneous bleeding may resolve rapidly after antivenom, laboratory abnormalities may resolve more slowly. Neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    appear to be of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central pressure monitoring may be useful in the titration of intravenous fluid in patients who have not responded to fluid challenge. Central lines should be inserted with caution in patients with significant coagulopathy. As noted above, the etiology of hypotension may be multifactorial. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hypotension and shock'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited published evidence concerning the management of rhabdomyolysis following snake bite; as a result, the recommended approach is extrapolated from crush injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/38\">",
"     38",
"    </a>",
"    ]. Plasma volume expansion with intravenous isotonic saline should be given as soon as possible. Treatment following initial fluid resuscitation often consists of alkaline-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    diuresis to a goal urine pH of 6.5.",
"   </p>",
"   <p>",
"    However, there is no clear clinical evidence that an alkaline diuresis is more effective than a saline diuresis; there is a potential risk to alkalinization, since it can promote the precipitation of calcium phosphate and induce or exacerbate hypocalcemia, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    may be ineffective if renal injury has already occurred. At a minimum, optimization of fluid status and the avoidance of drugs known to adversely affect renal function are of primary importance in the management of significant rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine output should be monitored closely, since oliguria in patients who have been adequately volume repleted usually portends significant renal failure. Central pressure monitoring may be useful in titrating further fluid therapy. Short-term dialysis may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cobra spit ophthalmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venom of the spitting cobras (Naja spp.) found in Asia and Africa can cause corneal damage if introduced into the eye. Acutely, the eye should be irrigated with copious quantities of water or saline. Slit lamp examination and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining should be performed to confirm corneal ulceration; topical antibiotic ointment should be applied if this is present. The instillation of diluted antivenom is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31431/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12981216\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Websites that provide information about specific regions or snake species include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A database and image library to assist clinicians with identifying the most important venomous snakes by country or region and finding antivenom products. (",
"      <a class=\"external\" href=\"file://apps.who.int/bloodproducts/snakeantivenoms/database/\">",
"       file://apps.who.int/bloodproducts/snakeantivenoms/database/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guidelines for the management of patients following snake bite in South East Asia (",
"      <a class=\"external\" href=\"file://www.toxinology.org/resources/protocols/who-searo snakebite guidelines 2010 copy.pdf\">",
"       www.toxinology.org/resources/protocols/WHO-SEARO%20Snakebite%20Guidelines%202010%20copy.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guidelines for recognition and management of Australian snake bites (",
"      <a class=\"external\" href=\"file://www.resus.org.au/policy/guidelines/section_9/guideline_9-4-1-july11.pdf\">",
"       www.resus.org.au/policy/guidelines/section_9/guideline_9-4-1-july11.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An extensive database of the distribution of snake species and clinical manifestations of different snake species bites (",
"      <a class=\"external\" href=\"file://www.toxinology.com/\">",
"       www.toxinology.com",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A list of antivenoms and suppliers (",
"      <a class=\"external\" href=\"file://toxinfo.org/antivenoms\">",
"       file://toxinfo.org/antivenoms",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A global directory of poisons information centers (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of snake envenomation varies widely between region and local knowledge is vital in determining treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12981104\">",
"    <span class=\"h2\">",
"     First aid",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Field management is directed toward delaying systemic absorption of venom and expediting transport to the hospital. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Field management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pressure immobilization should only be used for envenomation where the risk of local necrosis is low and the consequences of systemic toxicity is high (eg, neurotoxicity). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pressure immobilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6320518\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Envenomation syndromes include local and systemic features. The major syndromes of systemic envenomation include neurotoxicity, coagulopathy, shock, rhabdomyolysis and renal failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hospital assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6320532\">",
"    <span class=\"h2\">",
"     Evaluation and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knowledge of the toxicity profiles of local snake species is vital, and expert advice should be sought if snake bite is uncommon. Clinical and laboratory assessment should be focused on specific syndromes, including local effects, paralysis, coagulopathy, shock, muscle damage, and renal failure. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Specific management of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antivenom is indicated with significant local envenomation or evidence of systemic envenomation but may be accompanied by significant allergic phenomena. The decision to give antivenom must be based on the risks and benefits of administration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antivenom'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of both envenomation and the administration of antivenom should be anticipated. Ongoing management is supportive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adverse reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Specific management of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Websites that provide information about specific regions or snake species are provided above. (See",
"      <a class=\"local\" href=\"#H12981216\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/1\">",
"      Chippaux JP. Snake-bites: appraisal of the global situation. Bull World Health Organ 1998; 76:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/2\">",
"      Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/3\">",
"      Cheng AC, Currie BJ. Venomous snakebites worldwide with a focus on the Australia-Pacific region: current management and controversies. J Intensive Care Med 2004; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/4\">",
"      Blackman JR, Dillon S. Venomous snakebite: past, present, and future treatment options. J Am Board Fam Pract 1992; 5:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/5\">",
"      Sutherland SK, Coulter AR, Harris RD. Rationalisation of first-aid measures for elapid snakebite. Lancet 1979; 1:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/6\">",
"      Pearn J, Morrison J, Charles N, Muir V. First-aid for snake-bite: efficacy of a constrictive bandage with limb immobilization in the management of human envenomation. Med J Aust 1981; 2:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/7\">",
"      Murrell G. The effectiveness of the pressure/immobilization first aid technique in the case of a tiger snake bite. Med J Aust 1981; 2:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/8\">",
"      Hall EL. Role of surgical intervention in the management of crotaline snake envenomation. Ann Emerg Med 2001; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/9\">",
"      Stewart ME, Greenland S, Hoffman JR. First-aid treatment of poisonous snakebite: are currently recommended procedures justified? Ann Emerg Med 1981; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/10\">",
"      Alberts MB, Shalit M, LoGalbo F. Suction for venomous snakebite: a study of \"mock venom\" extraction in a human model. Ann Emerg Med 2004; 43:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/11\">",
"      Mosquera A, Idrovo LA, Tafur A, Del Brutto OH. Stroke following Bothrops spp. snakebite. Neurology 2003; 60:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/12\">",
"      Sutherland SK. Deaths from snake bite in Australia, 1981-1991. Med J Aust 1992; 157:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/13\">",
"      Otero R, Guti&eacute;rrez J, Beatriz Mesa M, et al. Complications of Bothrops, Porthidium, and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital. Toxicon 2002; 40:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/14\">",
"      Sano-Martins IS, Fan HW, Castro SC, et al. Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration in patients envenomed by Bothrops snakes. Butantan Institute Antivenom Study Group. Toxicon 1994; 32:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/15\">",
"      Yip L. Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite. Ann Emerg Med 2002; 39:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/16\">",
"      Pinho FM, Zanetta DM, Burdmann EA. Acute renal failure after Crotalus durissus snakebite: a prospective survey on 100 patients. Kidney Int 2005; 67:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/17\">",
"      Currie BJ. Snakebite in Australia: moving from anecdotes to prospective studies. Emerg Med (Fremantle) 2003; 15:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/18\">",
"      Warrell DA. Bites of venomous snakes. N Engl J Med 2002; 347:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/19\">",
"      Jorge MT, Malaque C, Ribeiro LA, et al. Failure of chloramphenicol prophylaxis to reduce the frequency of abscess formation as a complication of envenoming by Bothrops snakes in Brazil: a double-blind randomized controlled trial. Trans R Soc Trop Med Hyg 2004; 98:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/20\">",
"      Kularatne SA, Kumarasiri PV, Pushpakumara SK, et al. Routine antibiotic therapy in the management of the local inflammatory swelling in venomous snakebites: results of a placebo-controlled study. Ceylon Med J 2005; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/21\">",
"      WHO/SEARO Guidelines for the clinical management of snake bites in the Southeast Asian region. Southeast Asian J Trop Med Public Health 1999; 30(Suppl 1):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/22\">",
"      Morrison JJ, Pearn JH, Covacevich J, Nixon J. Can Australians identify snakes? Med J Aust 1983; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/23\">",
"      Sutherland SK. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits. Med J Aust 1992; 157:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/24\">",
"      Jelinek GA, Hamilton T, Hirsch RL. Admissions for suspected snake bite to the Perth adult teaching hospitals, 1979 to 1988. Med J Aust 1991; 155:761.",
"     </a>",
"    </li>",
"    <li>",
"     Warrell D. Treatment of snake bite in the Asia Pacific region: A personal view. In: Snakes of Medical Importance (Asia Pacific Region), Gopalakrishnajone P, Chao L (Eds), National University of Singapore, Singapore 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/26\">",
"      Lalloo DG, Theakston RD. Snake antivenoms. J Toxicol Clin Toxicol 2003; 41:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/27\">",
"      Premawardhena AP, de Silva CE, Fonseka MM, et al. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. BMJ 1999; 318:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/28\">",
"      Gawarammana IB, Kularatne SA, Dissanayake WP, et al. Parallel infusion of hydrocortisone +/- chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med J Aust 2004; 180:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/29\">",
"      Fan HW, Marcopito LF, Cardoso JL, et al. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites. BMJ 1999; 318:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/30\">",
"      Cheng AC, Winkel KD. Antivenom efficacy, safety and availability: measuring smoke. Med J Aust 2004; 180:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/31\">",
"      Christensen PA. The stability of refined antivenin. Toxicon 1975; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/32\">",
"      Wilson SC, Vrahas MS, Berson L, Paul EM. A simple method to measure compartment pressures using an intravenous catheter. Orthopedics 1997; 20:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/33\">",
"      Hudson BJ. Positive response to edrophonium in death adder (Acanthophis antarcticus) envenomation. Aust N Z J Med 1988; 18:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/34\">",
"      Flachsenberger W, Mirtschin P. Anticholinesterases as antidotes to envenomation of rats by the death adder (Acanthophis antarcticus). Toxicon 1994; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/35\">",
"      Watt G, Theakston RD, Hayes CG, et al. Positive response to edrophonium in patients with neurotoxic envenoming by cobras (Naja naja philippinensis). A placebo-controlled study. N Engl J Med 1986; 315:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/36\">",
"      Tun Pe. Heparin therapy in Russell's viper bite victims with disseminated intravascular coagulation: a controlled trial. Southeast Asian J Trop Med Public Health 1992; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/37\">",
"      Kelen EM, Rosenfeld G, Vainzof M, Machado ZC. Experimental defibrination and bothropase: a study on the fibrinolytic mechanism in vivo. Haemostasis 1978; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31431/abstract/38\">",
"      Smith J, Greaves I. Crush injury and crush syndrome: a review. J Trauma 2003; 54:S226.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6594 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31431=[""].join("\n");
var outline_f30_44_31431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIELD MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pressure immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methods not recommended",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HOSPITAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation of the bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypotension and shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antivenom",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Failure to respond",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specific management of complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Local",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cobra spit ophthalmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12981216\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12981104\">",
"      First aid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6320518\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6320532\">",
"      Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6594|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/62/36842\" title=\"figure 1\">",
"      First aid snake bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6594|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/19/15676\" title=\"table 1\">",
"      Snake venom syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31432="Approach to the adult with metabolic acidosis";
var content_f30_44_31432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with metabolic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31432/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/44/31432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each day approximately 15,000 mmol of carbon dioxide (which can generate carbonic acid as it combines with water) and 50 to 100 meq of nonvolatile acid (mostly sulfuric acid derived from the metabolism of sulfur-containing amino acids) are produced. Acid-base balance is maintained by pulmonary and renal excretion of carbon dioxide and nonvolatile acid, respectively.",
"   </p>",
"   <p>",
"    Renal excretion of acid involves the combination of hydrogen ions with urinary titratable acids, particularly phosphate (HPO42- &nbsp;+ &nbsp;H+ &nbsp; &mdash;&gt; &nbsp; H2PO4-), or with ammonia to form ammonium (NH3 &nbsp;+ &nbsp;H+ &nbsp; &mdash;&gt; &nbsp; NH4+) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1\">",
"     1",
"    </a>",
"    ]. The latter is the primary adaptive response, since ammonia production from the metabolism of glutamine can be appropriately increased in the presence of an acid load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acid-base balance is usually assessed in terms of the bicarbonate-carbon dioxide buffer system:",
"   </p>",
"   <p>",
"    &nbsp;Dissolved CO2 &nbsp;+ &nbsp;H2O &nbsp;&lt;&mdash;&gt; &nbsp;H2CO3 &nbsp; &lt;&mdash;&gt; &nbsp; HCO3- &nbsp;+ &nbsp;H+",
"   </p>",
"   <p>",
"    The concentration of H2CO3 (carbonic acid) is normally so low that its role can be ignored and the ratio between the reactants can be expressed by the Henderson-Hasselbalch equation:",
"   </p>",
"   <p>",
"    &nbsp;pH &nbsp; = &nbsp; 6.10 &nbsp; + &nbsp; log &nbsp;([HCO3-] &nbsp;&divide; &nbsp;[0.03 &nbsp;x &nbsp;PCO2])",
"   </p>",
"   <p>",
"    where the pH is equal to (-log [H+]), 6.10 is the pKa (equal to -log Ka), Ka is the dissociation constant for the reaction, 0.03 is equal to the solubility constant for CO2 in the extracellular fluid, and PCO2 is equal to the partial pressure of carbon dioxide in the extracellular fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23224?source=see_link\">",
"     \"Chapter 10B: Buffers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the adult with metabolic acidosis will be reviewed here. The approach in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=see_link\">",
"     \"Approach to the child with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis can be defined as a low arterial pH (normal 7.40, with a range of 7.35-7.45) and a low serum bicarbonate concentration (normal 24",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    with a range of 22-28",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"   </p>",
"   <p>",
"    Metabolic",
"    acidosis can be produced by three major mechanisms, with the major individual causes being discussed in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"mobipreview.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased acid generation",
"     </li>",
"     <li>",
"      Loss of bicarbonate",
"     </li>",
"     <li>",
"      Diminished renal acid excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to classifying metabolic acidosis by mechanism, a second system classifies by whether the anion gap is normal or increased. This system is primarily used for determining the cause of metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Serum anion gap and differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased acid generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased acid generation leading to metabolic acidosis occurs in a variety of clinical settings, which are discussed in detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactic acidosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=see_link\">",
"       \"Causes of lactic acidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ketoacidosis due to uncontrolled diabetes mellitus, excess alcohol intake, or fasting (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6613?source=see_link\">",
"       \"Alcoholic and fasting ketoacidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ingestions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Methanol or ethylene glycol (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toluene (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=see_link\">",
"       \"Inhalant abuse in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21526?source=see_link&amp;anchor=H8#H8\">",
"       \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Toluene inhalation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Loss of bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis due to loss of bicarbonate occurs in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea or ureteral diversion as the ureters are implanted into the sigmoid colon or a short loop of ileum (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Proximal (type 2) renal tubular acidosis, in which proximal bicarbonate reabsorption is impaired (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=see_link&amp;anchor=H42786907#H42786907\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Proximal (type 2) RTA'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, among patients with ketoacidosis, the excretion of ketoacid anions in the urine with sodium or potassium represents the loss of potential bicarbonate since, if not excreted, the ketoacids would be metabolized, a process that results in regeneration of bicarbonate lost in the initial buffering reaction. The net effect is that most patients with diabetic ketoacidosis develop a normal anion gap metabolic acidosis following insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21526?source=see_link&amp;anchor=H5#H5\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Urinary loss of unmeasured anions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diminished renal acid excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A regular western diet generates a daily acid load of approximately 50 to 100",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"    Balance is maintained by excreting these extra hydrogen ions in the urine. There are two causes of metabolic acidosis in which the acidosis is due to diminished renal acid excretion: renal failure and distal (type 1) renal tubular acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Development of metabolic acidosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197401411\">",
"    <span class=\"h2\">",
"     Dilution acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term dilution acidosis refers to a fall in serum bicarbonate concentration that is solely due to expansion of the extracellular fluid volume as could occur with the administration of large volumes of intravenous fluid that does not contain bicarbonate or an anion that can be metabolized to bicarbonate such as lactate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/4\">",
"     4",
"    </a>",
"    ]. In this setting, the fall in serum bicarbonate is substantially less than predicted from the degree of volume expansion, presumably due to the contribution of intracellular and bone buffers. In an animal model, for example, volume expansion with isotonic saline that caused a 28 percent dilution of extracellular volume resulted in a fall in serum bicarbonate of only 10 percent (eg, from 24 to 22",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    if this applied to humans) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, dilution acidosis is not likely to produce a marked metabolic acidosis unless an extraordinarily large volume of isotonic fluid containing neither acids nor alkali is infused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPENSATORY RESPIRATORY RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of metabolic acidosis is associated with a compensatory respiratory response. The Henderson-Hasselbalch equation shows that the pH is determined by the ratio between the HCO3 concentration and PCO2, not by the value of either one alone. Thus, the body responds to any acid-base disorder by making compensatory respiratory or renal responses in an attempt to normalize the pH. These responses are probably mediated at least in part by parallel alterations in pH in renal tubular or respiratory center cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protection of the",
"    <span class=\"nowrap\">",
"     HCO3/PCO2",
"    </span>",
"    ratio and therefore the pH requires a compensatory response that varies in the same direction as the primary disorder. Thus, in metabolic acidosis, ventilation is increased, resulting in a fall in PCO2, which tends to raise the pH toward normal.",
"   </p>",
"   <p>",
"    The respiratory compensation results in a 1.2 mmHg fall in the PCO2 for every 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in the serum bicarbonate concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. This response begins within the first 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/8\">",
"     8",
"    </a>",
"    ] and is complete by 12 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/9\">",
"     9",
"    </a>",
"    ]. An inability to generate this hyperventilatory response is generally indicative of significant underlying respiratory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF METABOLIC ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of any acid-base disorder begins with measurement of the serum bicarbonate concentration and the arterial pH and PCO2. Measurement of the serum bicarbonate concentration alone is not sufficient, since a low serum bicarbonate concentration can represent the primary change in metabolic acidosis or the compensatory response in respiratory alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a simple metabolic acidosis requires a low serum bicarbonate and a low extracellular pH. Once the disorder is diagnosed, the degree of compensation should then be assessed. As an example, a 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in the serum bicarbonate concentration to 14",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    should be associated with an approximately 12 mmHg decline in the PCO2 (1.2 mmHg fall in the PCO2 for every 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    reduction in the serum bicarbonate concentration) to 28 mmHg. If the PCO2 is substantially higher or lower than this value, then the patient also has a respiratory acidosis or alkalosis, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis may be more complicated in patients with combined disorders in which the metabolic acidosis is the less prominent component. This issue is discussed in detail elsewhere but can be illustrated here. Suppose a patient with chronic respiratory acidosis, characterized by hypercapnia and a compensatory rise in the serum bicarbonate concentration, develops diarrhea. The loss of bicarbonate in the stool will lower the serum bicarbonate concentration and produce a metabolic acidosis but the serum bicarbonate concentration may still be above the \"normal\" range since the baseline value was high. In this setting, metabolic acidosis is defined as a serum bicarbonate concentration that is lower than it should be for the degree of chronic hypercapnia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SERUM ANION GAP AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with documented metabolic acidosis, determination of the serum anion gap (AG) is an important step in approaching the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"mobipreview.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1,3,11\">",
"     1,3,11",
"    </a>",
"    ]. The serum AG is calculated from the following formula:",
"   </p>",
"   <p>",
"    Serum AG &nbsp;= &nbsp;Measured cations - measured anions",
"   </p>",
"   <p>",
"    Since sodium (Na) is the primary measured cation and chloride (Cl) and bicarbonate (HCO3) are the primary measured anions:",
"   </p>",
"   <p>",
"    Serum AG &nbsp;= &nbsp;Na - (Cl &nbsp;+ &nbsp;HCO3)",
"   </p>",
"   <p>",
"    Some physicians also include the serum potassium in the formula; when this done, the normal range increases by about 4",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Serum AG &nbsp;= &nbsp;(Na &nbsp;+ &nbsp;K) &nbsp;- &nbsp;(Cl &nbsp;+ &nbsp;HCO3)",
"   </p>",
"   <p>",
"    In normal subjects, the serum AG is primarily determined by the negative charges on the serum proteins, particularly albumin. As a result, the expected normal values for the AG must be adjusted downward in patients with hypoalbuminemia, with the serum AG falling by 2.3 to 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    reduction in the serum albumin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of the serum AG is most accurate when serial measurements are available from the same laboratory (including baseline values). The normal serum AG had been considered to range between 7 and 13",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, the normal value may be as low as 3 to 11",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (averaging 6",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    due to a higher chloride concentration measured with the newer autoanalyzers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. As a result, knowing the normal range in a particular laboratory is essential if the serum AG is to be interpreted properly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors that affect the serum AG can be most easily appreciated by rewriting the first equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to being equal to the difference between measured cations and anions, the serum AG is also equal to:",
"   </p>",
"   <p>",
"    &nbsp;Serum AG &nbsp;= &nbsp;Unmeasured anions - unmeasured cations",
"   </p>",
"   <p>",
"    Thus, an increase in the AG can be induced by a fall in unmeasured cations (hypocalcemia or hypomagnesemia) or, more commonly and more markedly, by a rise in unmeasured anions, as with the accumulation of lactate in lactic acidosis or ketoacid anions in ketoacidosis or hyperalbuminemia due to volume contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alterations in the concentration of unmeasured anions and cations can lead to misestimation of the baseline serum AG. As an example, both hypoalbuminemia (decreased unmeasured anions) and hyperkalemia (increased unmeasured cations) can lower the serum AG. A patient with both of these disorders could have a baseline serum AG of 2 rather than 8",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In this setting, a serum AG of 14",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which is only moderately above the normal range, represents a true elevation in the serum AG of as much as 12",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    The strong ion difference analysis is a complex alternative to the serum AG in analyzing acid-base disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/13\">",
"     13",
"    </a>",
"    ]. Although this analysis may be helpful in certain unusual settings, we and others prefer an approach based upon the serum AG because it is simpler and adequate in the vast majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/14\">",
"     14",
"    </a>",
"    ]. This is particularly true if the clinician appropriately adjusts the values for the serum AG downward in patients with hypoalbuminemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20437?source=see_link\">",
"     \"Strong ions and the analysis of acid-base disturbances (Stewart approach)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Normal anion gap acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with metabolic acidosis, there is buffering of excess acid by extracellular bicarbonate. If, for example, the acid were hydrochloric acid (HCl), then:",
"   </p>",
"   <p>",
"    &nbsp;HCl &nbsp;+ &nbsp;NaHCO3 &nbsp;&mdash;&gt; &nbsp;NaCl &nbsp;+ &nbsp;H2CO3 &nbsp;&mdash;&gt; &nbsp;CO2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    In this setting, bicarbonate is replaced on an equimolar basis by chloride and there is no change in the serum AG. This disorder is also called a hyperchloremic acidosis because of the rise in the serum chloride concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar sequence occurs in several clinical settings (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"mobipreview.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ). Both diarrhea and proximal (type 2) renal tubular acidosis can lead to the loss of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . The kidneys compensate by retaining sodium chloride in an attempt to preserve volume, with the net effect being a milliequivalent-for-milliequivalent exchange of chloride for bicarbonate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"     \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with renal failure also have a normal AG acidosis. Each day, the metabolism of dietary proteins generates 50 to 100 meq of acid, mostly as H2SO4 (sulfuric acid) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3\">",
"     3",
"    </a>",
"    ]. If there is a prominent impairment in tubular function, then both hydrogen secretion and sulfate reabsorption may be impaired. The net result is the retention of hydrogen (leading to metabolic acidosis) and the excretion of SO4 as the sodium or potassium salt (maintaining a normal serum AG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3,15\">",
"     3,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar considerations apply when hydrogen is retained because of impaired renal acid excretion due to distal (type 1) renal tubular acidosis or hypoaldosteronism. In both of these conditions, a normal AG acidosis is seen since there is no retention of unmeasured anions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, as described in the following section, a normal anion gap acidosis typically occurs after the successful treatment of ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased anion gap acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased serum anion gap acidosis is seen when the excess acid consists of hydrogen with an anion other than chloride, such as lactate (L) in lactic acidosis. In this setting, the buffering reaction is as follows:",
"   </p>",
"   <p>",
"    &nbsp;HL &nbsp;+ &nbsp;NaHCO3 &nbsp;&mdash;&gt; &nbsp;NaL &nbsp;+ &nbsp;H2CO3 &nbsp;&mdash;&gt; &nbsp;CO2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    The acidosis is due to the retained hydrogen ion, while the increase in the unmeasured anion lactate will raise the serum AG.",
"   </p>",
"   <p>",
"    The diagnostic utility of a high serum AG is greatest when the AG is above 25",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    in this setting, one of the above conditions will almost always be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/16\">",
"     16",
"    </a>",
"    ]. In comparison, studies in both humans and animals have shown that it is often not possible to identify the unmeasured anions with a lesser elevation in the serum AG, particularly when the AG is less than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Increases in serum protein and phosphate concentrations may contribute, but other unidentified anions also appear to be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/17\">",
"     17",
"    </a>",
"    ]. Some evidence suggests that these unmeasured anions include citrate, isocitrate, alpha-ketoglutarate, succinate, malate, and d-lactate, which are usually associated with the Krebs cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of a high AG metabolic acidosis include (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"mobipreview.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1,3,11\">",
"     1,3,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactic acidosis, usually due to marked systemic hypoperfusion or malignancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ketoacidosis due to diabetes mellitus, alcohol, or fasting, in which beta-hydroxybutyrate is the primary unmeasured anion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6613?source=see_link\">",
"       \"Alcoholic and fasting ketoacidosis\"",
"      </a>",
"      .) The serum AG may also be modestly elevated in nonketotic hyperglycemia even though there is little or no metabolic acidosis. In this setting, the release of phosphate and perhaps other anions from the cells may be responsible for the elevation in AG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum phosphate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In both lactic acidosis and ketoacidosis, the unmeasured anion is important physiologically. Correction of the underlying abnormality (eg, restoration of tissue perfusion in lactic acidosis, and insulin therapy in diabetic ketoacidosis) results in metabolism of the excess anion, which regenerates at least some of the bicarbonate that was lost during the initial buffering reaction.",
"      <br/>",
"      <br/>",
"      The elevation in serum AG in ketoacidosis is often less than expected from the fall in serum bicarbonate because of the loss of ketoacid anions (eg, beta-hydroxybutyrate) in the urine as the sodium or potassium salt. This does not occur in hypoperfusion-induced lactic acidosis since there is typically little or no renal function. If the ketoacid anions had remained in the extracellular fluid, their metabolism following insulin therapy would have regenerated the bicarbonate lost in the initial buffering reaction. Thus, the loss of ketoacid anions as the sodium or potassium salt represents the loss of what has been called \"potential bicarbonate.\" The net effect of the loss of potential bicarbonate is that almost all patients with diabetic ketoacidosis develop a usually mild normal AG acidosis after insulin therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Anion gap metabolic acidosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21526?source=see_link&amp;anchor=H5#H5\">",
"       \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Urinary loss of unmeasured anions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with renal failure, in whom there is retention of both hydrogen and anions, such as sulfate, phosphate, and urate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/3,15\">",
"       3,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ingestions, in which the major retained anions are formate with methanol, glycolate and oxalate with ethylene glycol, and ketones and lactate with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . However, metabolic acidosis may be absent and the serum anion gap may be normal in methanol or ethylene glycol intoxication if there is concurrent alcohol ingestion. Alcohol competes for the enzyme alcohol dehydrogenase, thereby minimizing the metabolism of methanol or ethylene glycol to their toxic metabolites. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are other, much less common causes of a high anion gap acidosis. As an example, inherited glutathione synthetase deficiency may result in an acidosis caused by the accumulation of pyroglutamic acid (5-oxoproline), a metabolic product of gamma-glutamyl-cysteine. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5399?source=see_link&amp;anchor=H7#H7\">",
"       \"Related disorders of the hexose monophosphate shunt and glutathione metabolism\", section on 'Glutathione synthetase deficiency'",
"      </a>",
"      .) An acquired form of pyroglutamic acidemia has also been described in which patients have a high anion gap acidosis, high concentrations of pyroglutamic acid, mental status changes, and a history of acetaminophen use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/21-24\">",
"       21-24",
"      </a>",
"      ]. The mechanism of action is thought to be glutathione depletion, resulting in increased formation of gamma-glutamyl-cysteine and then pyroglutamic acid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overlap",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be overlap between the causes of a normal and high AG metabolic acidosis. Two settings in which this can occur are diarrhea and diabetic ketoacidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea is typically associated with a normal AG acidosis. However, with severe diarrhea, as can occur in cholera, there may be an increase in the AG due to the triad of hypoperfusion-induced lactic acidosis, volume contraction-induced hyperalbuminemia (albumin is negatively charged and accounts for most of the AG in normal individuals), and hyperphosphatemia that results from acidemia-induced movement of phosphate out of the cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link&amp;anchor=H5#H5\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\", section on 'Serum anion gap'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis is typically associated with an elevated AG. However, if renal function and volume status are well maintained, some or many of the excess ketone anions will be excreted in the urine as the sodium and potassium salts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/26\">",
"       26",
"      </a>",
"      ]. The net effect is that the rise in the AG may be much less than expected from the severity of the metabolic acidosis. Furthermore, the loss of these organic anions is equivalent to the loss of bicarbonate, since metabolism of the ketoacid anions results in the regeneration of bicarbonate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Anion gap metabolic acidosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the absence of end-stage renal disease, a",
"    <strong>",
"     normal AG acidosis",
"    </strong>",
"    is seen during the treatment phase of almost all patients with diabetic ketoacidosis due to the urinary loss of these bicarbonate precursors. Similar considerations apply to D-lactic acidosis and toluene-induced metabolic acidosis, in which the anion gap may either be elevated (due to D-lactate and hippurate, respectively) or normal due to the rapid urinary excretion of the excess unmeasured anions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21526?source=see_link&amp;anchor=H5#H5\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Urinary loss of unmeasured anions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serum anion gap without metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the serum anion gap is primarily measured in patients with metabolic acidosis, it be increased, low, or even negative in conditions other than metabolic acidosis. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36533?source=see_link\">",
"     \"Serum anion gap in conditions other than metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of metabolic acidosis can vary markedly with the underlying disorder. The general principles of treatment in patients with metabolic acidosis will be reviewed here, including issues related to estimation of the bicarbonate deficit.",
"   </p>",
"   <p>",
"    The specific approaches to therapy in the most common causes of metabolic acidosis are discussed in detail separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic ketoacidosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link\">",
"       \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lactic acidosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diarrhea (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal tubular acidosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=see_link\">",
"       \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ingestions, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , methanol, and ethylene glycol (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy in metabolic acidosis is restoration of a normal extracellular pH. The normal renal response to metabolic acidosis is to markedly increase acid excretion, primarily as ammonium. Thus, exogenous alkali may not be required if the acidemia is not severe (arterial pH &gt;7.20), the patient is asymptomatic, and the underlying process, such as diarrhea, can be controlled.",
"   </p>",
"   <p>",
"    With more severe acidemia, correction can be achieved more rapidly by the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . The initial aim of therapy in most patients is to raise the systemic pH above 7.20; this is a level at which the major consequences of severe acidemia should not be observed.",
"   </p>",
"   <p>",
"    However, there is some uncertainty about the absolute benefits of achieving this level, particularly in patients with diabetic ketoacidosis and lactic acidosis (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"mobipreview.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In these disorders, initial buffering of the excess hydrogen ions by bicarbonate leaves an organic anion behind (beta-hydroxybutyrate and lactate, respectively). Treatment of the underlying disorder will permit metabolism of the organic anion, which regenerates most or all of bicarbonate lost in the initial buffering process. Thus, bicarbonate therapy is generally not given unless the arterial pH is below 7.00 in ketoacidosis or 7.10 to 7.15 in lactic acidosis. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calculation of bicarbonate deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuming that respiratory function is normal, attainment of a pH of 7.20 usually requires raising the serum bicarbonate to 10 to 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/29\">",
"     29",
"    </a>",
"    ]. The quantity of bicarbonate required can be estimated from the bicarbonate deficit:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;HCO3 deficit &nbsp; &nbsp;= &nbsp; &nbsp;HCO3 space &nbsp; x &nbsp; HCO3 deficit per liter",
"   </p>",
"   <p>",
"    The apparent bicarbonate space is a reflection of total body buffering capacity, which includes extracellular bicarbonate, intracellular proteins, and bone carbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. At a normal to moderately reduced serum bicarbonate concentration, excess hydrogen ions are buffered proportionately through the total body water and the apparent bicarbonate space is approximately 55 percent of lean body weight.",
"   </p>",
"   <p>",
"    However, the bicarbonate space",
"    <strong>",
"     rises",
"    </strong>",
"    in severe metabolic acidosis, since the fall in the serum bicarbonate concentration means that there is an ever increasing contribution from the cells and bone, which have a virtually limitless supply of buffer. Thus, the bicarbonate space can reach 70 percent when the serum bicarbonate concentration falls below 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and may exceed 100 percent at levels below 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/9\">",
"     9",
"    </a>",
"    ]. The bicarbonate space at a given serum bicarbonate concentration can be estimated from the following formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31432/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Bicarbonate space &nbsp; = &nbsp; [0.4 &nbsp;+ (2.6 &nbsp;&divide; &nbsp;[HCO3])] &nbsp;x &nbsp;lean body weight (in kg)",
"   </p>",
"   <p>",
"    If, for example, a patient with a lean body weight (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/26/29089?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/21/29009?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) of 60 kg has a serum bicarbonate concentration of 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the initial aim of therapy is to raise this value to 12",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The bicarbonate space is approximately 80 percent and 60 percent of body weight, respectively, at these two concentrations. Taking an average value of 70 percent:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Bicarbonate deficit &nbsp; &nbsp;= &nbsp; &nbsp;0.7 &nbsp; x &nbsp; 60 &nbsp; x &nbsp; (12 &nbsp; - &nbsp; 6) &nbsp; &nbsp;= &nbsp; &nbsp;252 meq",
"   </p>",
"   <p>",
"    Thus, approximately 250 meq of alkali (usually as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ) can be given over the first four to eight hours. However, this is only a rough estimation that cannot replace serial measurements of the extracellular pH. One potential problem is that the calculated deficit does not account for ongoing losses. If, for example, there is continuing acid loss from diarrhea, then the alkali requirements may be substantially increased.",
"   </p>",
"   <p>",
"    If the pH is raised to a safe level, then further alkali therapy may be unnecessary, since increased renal acid excretion will slowly regenerate the needed bicarbonate. If more alkali is given, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    or citrate (which is rapidly metabolized to bicarbonate) can replace intravenous therapy.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/1\">",
"      Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/2\">",
"      Garibotto G, Sofia A, Robaudo C, et al. Kidney protein dynamics and ammoniagenesis in humans with chronic metabolic acidosis. J Am Soc Nephrol 2004; 15:1606.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.583-588.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/4\">",
"      Garella S, Chang BS, Kahn SI. Dilution acidosis and contraction alkalosis: review of a concept. Kidney Int 1975; 8:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/5\">",
"      Garella S, Tzamaloukas AH, Chazan JA. Effect of isotonic volume expansion on extracellular bicarbonate stores in normal dogs. Am J Physiol 1973; 225:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/6\">",
"      Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med 1990; 150:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/7\">",
"      Bushinsky DA, Coe FL, Katzenberg C, et al. Arterial PCO2 in chronic metabolic acidosis. Kidney Int 1982; 22:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/8\">",
"      Wiederseiner JM, Muser J, Lutz T, et al. Acute metabolic acidosis: characterization and diagnosis of the disorder and the plasma potassium response. J Am Soc Nephrol 2004; 15:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/9\">",
"      Pierce NF, Fedson DS, Brigham KL, et al. The ventilatory response to acute base deficit in humans. Time course during development and correction of metabolic acidosis. Ann Intern Med 1970; 72:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/10\">",
"      Daniel SR, Morita SY, Yu M, Dzierba A. Uncompensated metabolic acidosis: an underrecognized risk factor for subsequent intubation requirement. J Trauma 2004; 57:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/11\">",
"      Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/12\">",
"      Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 2005; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/13\">",
"      Corey HE. Stewart and beyond: new models of acid-base balance. Kidney Int 2003; 64:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/14\">",
"      Emmett M. Anion-gap interpretation: the old and the new. Nat Clin Pract Nephrol 2006; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/15\">",
"      Wallia R, Greenberg A, Piraino B, et al. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986; 8:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/16\">",
"      Gabow PA, Kaehny WD, Fennessey PV, et al. Diagnostic importance of an increased serum anion gap. N Engl J Med 1980; 303:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/17\">",
"      Rackow EC, Mecher C, Astiz ME, et al. Unmeasured anion during severe sepsis with metabolic acidosis. Circ Shock 1990; 30:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/18\">",
"      Forni LG, McKinnon W, Lord GA, et al. Circulating anions usually associated with the Krebs cycle in patients with metabolic acidosis. Crit Care 2005; 9:R591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/19\">",
"      Forni LG, McKinnon W, Hilton PJ. Unmeasured anions in metabolic acidosis: unravelling the mystery. Crit Care 2006; 10:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/20\">",
"      Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/21\">",
"      Dempsey GA, Lyall HJ, Corke CF, Scheinkestel CD. Pyroglutamic acidemia: a cause of high anion gap metabolic acidosis. Crit Care Med 2000; 28:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/22\">",
"      Tailor P, Raman T, Garganta CL, et al. Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid). Am J Kidney Dis 2005; 46:e4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/23\">",
"      Fenves AZ, Kirkpatrick HM 3rd, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol 2006; 1:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/24\">",
"      Kortmann W, van Agtmael MA, van Diessen J, et al. 5-Oxoproline as a cause of high anion gap metabolic acidosis: an uncommon cause with common risk factors. Neth J Med 2008; 66:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/25\">",
"      Wang F, Butler T, Rabbani GH, Jones PK. The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med 1986; 315:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/26\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/27\">",
"      Adrogu&eacute; HJ, Madias NE. Management of life-threatening acid-base disorders. First of two parts. N Engl J Med 1998; 338:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/28\">",
"      Sabatini S, Kurtzman NA. Bicarbonate therapy in severe metabolic acidosis. J Am Soc Nephrol 2009; 20:692.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.628-633.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/30\">",
"      Adrogu&eacute; HJ, Brensilver J, Cohen JJ, Madias NE. Influence of steady-state alterations in acid-base equilibrium on the fate of administered bicarbonate in the dog. J Clin Invest 1983; 71:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31432/abstract/31\">",
"      Fernandez PC, Cohen RM, Feldman GM. The concept of bicarbonate distribution space: the crucial role of body buffers. Kidney Int 1989; 36:747.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2291 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31432=[""].join("\n");
var outline_f30_44_31432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased acid generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Loss of bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diminished renal acid excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197401411\">",
"      Dilution acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPENSATORY RESPIRATORY RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS OF METABOLIC ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SERUM ANION GAP AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Normal anion gap acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased anion gap acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overlap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serum anion gap without metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calculation of bicarbonate deficit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/0/38924\" title=\"table 1\">",
"      Causes of metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/26/29089?source=related_link\" title=\"calculator 1\">",
"      Calculator: Lean body weight (adult female)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?28/21/29009?source=related_link\" title=\"calculator 2\">",
"      Calculator: Lean body weight (adult male)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=related_link\">",
"      Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23224?source=related_link\">",
"      Chapter 10B: Buffers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5399?source=related_link\">",
"      Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36533?source=related_link\">",
"      Serum anion gap in conditions other than metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20437?source=related_link\">",
"      Strong ions and the analysis of acid-base disturbances (Stewart approach)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31433="Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications";
var content_f30_44_31433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Cornelia M Weyand, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/44/31433/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/44/31433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of atherosclerotic coronary artery disease (CAD) is increased in patients with chronic inflammatory rheumatic diseases, particularly those with systemic lupus erythematosus and rheumatoid arthritis (RA).",
"   </p>",
"   <p>",
"    The diagnostic and therapeutic implications related to CAD in patients with RA will be reviewed here. Other cardiac manifestations of RA, including pericarditis, myocarditis, atrioventricular block, valvular regurgitation, embolic events, and rheumatoid nodules, and the general clinical manifestations of RA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29815?source=see_link&amp;anchor=H5#H5\">",
"     \"Rheumatoid nodules\", section on 'Cardiac nodules'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, PATHOGENESIS, AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic evidence, possible pathogenetic mechanisms, and risk factors for CAD in RA are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief summary of the epidemiology, pathogenesis, and risk factors related to CAD in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with the general population, there is an increased incidence of cardiovascular events, including myocardial infarction, stroke, and cardiac death, in patients with RA. This increased risk is mediated by the presence of both traditional risk factors and factors unique to those with systemic inflammatory disorders.",
"     </li>",
"     <li>",
"      Chronic inflammation in RA may enhance the development of atherosclerosis, which is itself considered to be, at least in part, an inflammatory syndrome. Acceleration of atherosclerosis in patients with RA may be mediated by cytokines, immune complexes, abnormal function of the adaptive immune system, elevated levels of C-reactive protein, abnormal lipid metabolism, and endothelial dysfunction. Rarely, vasculitis may affect the coronary arteries.",
"     </li>",
"     <li>",
"      Use of antiinflammatory drugs such as glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), and selective cyclooxygenase-2 (COX-2) inhibitors may actually accelerate atherosclerosis and coronary thrombosis, while other agents may reduce cardiovascular risk (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and biologic agents, including tumor necrosis factor [TNF] inhibitors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of symptomatic CAD in patients with RA are typically similar to those without RA. However, a larger proportion of patients with RA has clinically silent CAD than do demographically similar individuals in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with RA are also less likely than those without RA to report chest pain during an acute coronary event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is uncertain why patients with RA and CAD are less likely to report chest pain prior to or during a cardiovascular event. Possible explanations are that patients with active arthritis or those with structural joint damage may be less physically active, less likely to place sufficient demand on the heart to elicit angina, and more likely to attribute pain to RA, or it may be that use of nonsteroidal antiinflammatory drugs, glucocorticoids, or disease-modifying antirheumatic drugs (DMARDs) alter pain perception.",
"   </p>",
"   <p>",
"    The approach to the diagnosis of CAD is generally similar in patients with and without RA. Given the enhanced incidence of CAD in this patient population, we suggest the performance of a yearly cardiovascular evaluation focused history and physical examination, as well as electrocardiography in patients &ge;50 years of age. There should also be a low threshold for proceeding to exercise or pharmacologic stress testing in those with symptoms or electrocardiographic findings suggestive of CAD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of chest pain in the general population is broad. This is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some causes of chest pain other than ischemic heart disease that are relatively unique to patients with RA. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sternoclavicular joint arthritis &mdash; Painful sternoclavicular joint involvement with localized tenderness may be present in up to 7 percent of patients with established, generalized rheumatoid arthritis. Rarely, involvement of the sternoclavicular joint is the initial manifestation of RA. Establishing the diagnosis is usually not difficult, once considered, since point tenderness favors local inflammation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2201?source=see_link&amp;anchor=H18#H18\">",
"       \"Major causes of musculoskeletal chest pain\", section on 'Rheumatoid arthritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericarditis &mdash; Acute painful pericarditis occurs in less than 10 percent of patients with RA during their lifetimes. Since small pericardial effusions are relatively common in patients without symptoms of pericarditis, caution is required in attributing chest pain to pericarditis based solely upon echocardiographic findings of an effusion. The major clinical manifestations of acute pericarditis are chest pain, pericardial friction rub, and the classic finding of widespread saddle-shaped or concave-up ST segment elevation on the electrocardiogram (ECG). Increasingly, cardiac magnetic resonance imaging is used to identify acute pericardial inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link\">",
"       \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpes zoster &mdash; The likelihood of herpes zoster infection is increased in a patient with RA receiving immunosuppressive medications, such as biologics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or high doses of glucocorticoids. It is characterized by a painful, unilateral vesicular eruption in a restricted dermatomal distribution. The diagnosis may be difficult prior to the appearance of the rash. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=see_link\">",
"       \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hypertension &mdash; Exertional chest pain indistinguishable from that of angina pectoris may be a manifestation of pulmonary hypertension, a rare complication of interstitial lung disease in patients with RA. Clinical evidence suggesting right ventricular dysfunction, such as pulmonary artery dilation on plain chest radiography and characteristic echocardiographic findings, may help distinguish chest pain symptoms related to pulmonary hypertension from angina pectoris. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortitis &mdash; Aortitis is a rare complication of RA, which, when present, is typically accompanied by rheumatoid vasculitis in other vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/4\">",
"       4",
"      </a>",
"      ]. Disease at the coronary ostia or associated coronary vasculitis can cause myocardial infarction. Dilatation of the ascending aorta is a common initial finding. Thoracic aortic dissection or rupture could cause chest pain. A &ldquo;ripping&rdquo; or &ldquo;tearing&rdquo; quality to the pain, associated back pain, pulse deficits, a difference in limb blood pressure of more than 10 mmHg, and hemodynamic compromise are suggestive of aortic dissection. An imaging study such as transthoracic or transesophageal echocardiography, magnetic resonance angiography, or contrast CT is necessary to confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22712?source=see_link\">",
"       \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest wall pain &mdash; Musculoskeletal pain in the chest wall is the most common cause of precordial chest pain in patients with RA and should be considered in the differential diagnosis of the RA patient with chest pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention (whether primary or secondary) and treatment of CAD are generally similar in patients with and without RA. Some issues that may be relatively unique to patients with RA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effects of systemic inflammation on CAD",
"     </li>",
"     <li>",
"      Benefits and adverse effects of glucocorticoids and other RA therapies",
"     </li>",
"     <li>",
"      Issues related to concomitant use of nonaspirin NSAIDs, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      selective COX-2 inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General prevention issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary prevention strategy of identifying modifiable risk factors for coronary heart disease and of employing interventions such as smoking cessation, lipid lowering, healthy diet, moderate exercise, weight control, and blood pressure control is widely recommended in the general population to reduce the risk of cardiovascular events and cardiovascular deaths. They should also be employed in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/5\">",
"     5",
"    </a>",
"    ]. These general preventive strategies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Limiting glucocorticoid exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic use of supraphysiologic doses of glucocorticoids may be associated with increased rates of myocardial infarction, stroke, heart failure, and all-cause mortality. These effects may be mediated, at least in part, by elevated lipoprotein levels. The risk of cardiovascular disease with use of systemic glucocorticoids is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H9#H9\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H10#H10\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Lipids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such adverse effects of chronic glucocorticoid therapy, including dyslipidemia, are typically seen at doses of 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or higher and may be increased at lower doses as well. When chronic therapy is required, it is, therefore, prudent to quickly taper the dose of glucocorticoids to the lowest effective dose, usually 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent, based upon disease activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lipid lowering with statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively limited data are available concerning the efficacy and safety of statins in patients with RA. Lipid lowering with a statin can be an effective primary prevention strategy for cardiovascular disease (CVD) in selected patients in the general population, including healthy individuals with normal lipid levels and an elevated serum C-reactive protein. However, the available data are insufficient, in our view, to warrant the use of statins in patients whose sole evidence of increased cardiovascular risk is the presence of rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'JUPITER trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial (TARA) that addressed the lipid lowering and antiinflammatory efficacy of statin therapy in active RA, 116 such patients with mean serum LDL-cholesterol levels of approximately 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were assigned to placebo or to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/6\">",
"     6",
"    </a>",
"    ]. Atorvastatin therapy was associated with significantly greater reductions in LDL-cholesterol levels (54 versus 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4 versus 0.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and in markers of inflammation such as serum C-reactive protein, the erythrocyte sedimentation rate, and indices of disease activity such as DAS28. The drug was well-tolerated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=see_link&amp;anchor=H2#H2\">",
"     \"Miscellaneous novel therapies in rheumatoid arthritis\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the lipid lowering and antiinflammatory effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in the TARA trail are of interest, but the trial was not designed to assess cardiovascular outcomes. In the absence of such data, we are reluctant to recommend statin therapy solely to improve cardiovascular outcomes in patients with RA who do not have traditional risk factors. The question of whether statins may have a role in treating joint inflammation in patients with refractory RA requires further study.",
"   </p>",
"   <p>",
"    Given the low rate of serious side effects from statins and the demonstrated antiinflammatory effects upon a number of pathways, it is reasonable to have a lower threshold for initiating these drugs in patients with active RA than in those without the disease. Although statins may have beneficial effects on lipid lowering and inflammation, their use should not be considered a substitute either for cardiovascular risk factor modification through lifestyle changes and other interventions or for use of indicated disease-modifying antirheumatic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an emerging risk factor for CAD, RA is not considered in recommendations for lipid lowering as a primary prevention strategy for CVD. However, in a study of 353 outpatients with RA, the magnitude of risk for CVD was comparable to the risk imposed by type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, a diagnosis of RA is not considered alone as an indication for statin therapy. However, some experts have proposed that the diagnosis of RA may constitute a risk equivalent and that patients with RA should routinely be placed on lipid lowering therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/7\">",
"     7",
"    </a>",
"    ]. This issue remains controversial, as statins are not free of side effects, and their effect in slowing progression of arthrosclerosis in RA has not been adequately tested.",
"   </p>",
"   <p>",
"    The evidence remains inconclusive as to whether statins can reduce risk for cardiovascular events in patients with RA as they do in individuals without RA, although there is widespread agreement that clinicians should have a high degree of alertness to monitor patients with RA for CVD and to manage risk factors aggressively. Appropriate trials testing the effects of stains on CV end points in patients with RA are needed to resolve these issues. Such trials are underway and will help to develop management guidelines. They can also contribute to a better pathophysiologic understanding of the inflammatory pathways that sustain atherosclerosis in those without and those with RA. The pathophysiology of the low-grade inflammation implicated in promoting atherosclerotic disease may differ from the low-grade inflammation typically encountered in RA, and these processes may each require distinct therapeutic interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264629617\">",
"    <span class=\"h3\">",
"     Our approach to general prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the recommendations developed by the European League Against Rheumatism (EULAR) for cardiovascular risk management in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/5\">",
"     5",
"    </a>",
"    ]. The EULAR recommendations stress the need for aggressive management of traditional risk factors and for optimization of antiinflammatory therapy. Additionally, the expert panel suggested the use of multivariate cardiovascular risk score models, such as the SCORE method (often used in Europe) or the Framingham risk model (often used in the United States), to estimate 10-year risk of cardiovascular disease and to determine the need for statins in an individual patient. Notably, the panel also recommended that the risk score used in these models should be multiplied by a factor of 1.5 in patients with RA who satisfy at least two of three criteria; these criteria include disease for longer than 10 years, positive testing for anticyclic citrullinated peptide (CCP) antibodies or rheumatoid factor, and the presence of extraarticular manifestations. The use of multivariate risk models for the estimation of cardiovascular risk in individual patients and the use of statins for lipid management in the primary and secondary prevention of CVD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H8#H8\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Multivariate risk models'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H10#H10\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'SCORE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure may be raised modestly by nonselective nonsteroidal antiinflammatory drugs (NSAIDs), selective COX-2 inhibitors, and glucocorticoids. Thus, for those in whom these agents are necessary, monitoring of blood pressure before and after starting such medications, with initiation or adjustment of antihypertensive therapy to maintain optimal blood pressure control, is suggested as a means of reducing the risk of CVD. Early initiation of DMARDs in most patients may avoid the need for regular use of NSAIDs or selective COX-2 inhibitors and may reduce the need for glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H12#H12\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Kidney and systemic hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult or impossible for patients with RA and either active synovitis or structural damage to joints of the lower extremities to perform the desired level of aerobic exercise. Exercise programs should be prescribed by a physical therapist and should be tailored for each patient&rsquo;s disease severity, body build, and previous activity level. High-intensity weightbearing exercises may not be appropriate for patients with preexisting structural damage of lower extremity joints. Less intense or non-weightbearing exercises are alternatives for such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of many, but not all, nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with an increased risk of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/10\">",
"     10",
"    </a>",
"    ]. These observations may have important implications for the selection of agents used to treat patients with RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Selective COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in detail elsewhere, all of the selective COX-2 inhibitors appear to have some potential cardiovascular risk. As a result, these agents should be avoided in the patient with RA who is not at high risk for gastroduodenal damage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nonselective NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of nonselective NSAIDs on cardiovascular outcomes in patients with RA is not well-studied. In the general population, nonselective NSAIDs have no significant benefit on cardiovascular risk, and the available data suggest an adverse effect with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Effect on cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a protective effect was suggested in an observational study of 923 patients with inflammatory polyarthritis from a primary care-based inception cohort, of whom two-thirds were eventually diagnosed with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/11\">",
"     11",
"    </a>",
"    ]. All-cause and CVD mortality were significantly reduced in association with baseline NSAID use (adjusted odds ratio 0.62 and 0.54). Only 4.4 percent of patients were receiving DMARDs. The most often used NSAIDs were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (27, 17, and 17 percent).",
"   </p>",
"   <p>",
"    The authors could not explain the difference in cardiovascular outcomes between the general population and patients with inflammatory polyarthritis and raised the possibility that unmeasured confounders may have influenced a doctor&rsquo;s decision to prescribe NSAIDs.",
"   </p>",
"   <p>",
"    At the least, the findings in this study suggest that the increased cardiovascular risk seen in patients with RA is not due to the use of NSAIDs. They are consistent with the observation that control of inflammation with disease-modifying antirheumatic drugs can reduce cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Control of inflammation due to RA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Our approach to NSAID use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach is unclear in the patient with RA who is at high risk for gastroduodenal damage (ie, who has one or more risk factors for developing NSAID-associated gastroduodenal ulcer and complications). Specific issues include the presence or absence of CVD, the specific risk for gastroduodenal damage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need for long-term oral anticoagulation.",
"   </p>",
"   <p>",
"    Among patients with both RA and CAD, our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We avoid the use of selective COX-2 inhibitors in patients with an average risk for gastroduodenal ulcers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"       \"Overview of selective COX-2 inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We use a nonselective NSAID (preferably",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ) and a proton pump inhibitor in patients at increased risk for gastroduodenal complications of NSAID therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , which does not interfere with platelet function, in the lowest effective dose for patients with CAD receiving anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or other vitamin-K antagonists for whom the use of nonselective NSAIDs is associated with an unacceptable risk of serious bleeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H18#H18\">",
"       \"Therapeutic use of warfarin\", section on 'Use of NSAIDs and antiplatelet agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative approach for such patients is the use of a glucocorticoid at the lowest effective dose instead of a COX-2 selective inhibitor. A similar approach is suggested for those receiving the antiplatelet drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific recommendations concerning the use of selective COX-2 inhibitors in patients without a diagnosis of CVD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is a mainstay of prevention of recurrent cardiovascular events in patients with an established diagnosis of coronary heart disease and in some patients with ischemic stroke. Aspirin may also have a role in the primary prevention of coronary heart disease. These aspects of low-dose aspirin use in primary and secondary prevention in the general patient population are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among those with RA, the use of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in primary or secondary prevention of CAD may be complicated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonselective nonaspirin NSAIDs may interfere with the beneficial effects of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      when used for prevention of CVD. This interaction is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The COX-2 selective agents do not appear to interfere with the antiplatelet effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . In addition, the risk of coronary events appears to be less with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      than with rofecoxib. Nevertheless, until the issue of cardiovascular safety is clarified, it is prudent to also avoid the use of COX-2 selective drugs in patients without a diagnosis of CAD but with multiple risk factors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether or not low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    mitigates the cardiovascular risk in patients who use COX-2 selective agents is uncertain. Limited data from clinical trials of at least two COX-2 inhibitors, rofecoxib (subsequently withdrawn from the market) and lumiracoxib, suggest that concomitant low-dose aspirin may reduce the risk of cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link&amp;anchor=H2#H2\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Ischemic cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Control of inflammation due to RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the hypothesis has not been adequately tested in a prospective trial, observational data suggest that strict control of inflammation in RA by use of therapy that effectively decreases synovial inflammation may favorably affect some CVD risk factors and may reduce the development and progression of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/13\">",
"     13",
"    </a>",
"    ]. These data are strongest for treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or tumor necrosis factor (TNF) inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/5\">",
"     5",
"    </a>",
"    ]. One of the mechanisms that may contribute to reduction of risk is an improvement in lipid profiles that may be associated with treatment with DMARD therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of benefit from use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study of 1240 patients with RA at one clinical center in North America addressed the question of a possible survival benefit among those treated with MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/15\">",
"       15",
"      </a>",
"      ]. After adjustment for possible confounding factors, the hazard ratio for death due to CVD among MTX-treated patients was significantly less than that for those who did not receive MTX (hazard ratio 0.3, 95% CI 0.2-0.7). This study is discussed in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 2010 systematic review suggests that the use of MTX in the treatment of RA is associated with a reduced risk of CVD events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/16\">",
"       16",
"      </a>",
"      ]. As an example, favorable effects of MTX treatment on cardiovascular risk factors were observed in a study that followed 40 patients with early RA (disease duration less than one year) treated with MTX and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/17\">",
"       17",
"      </a>",
"      ]. Lipid levels and ultrasonographically determined carotid artery intima-media thickness as a surrogate for atherosclerosis were measured. After a year of treatment, there were significant increases in mean HDL and decreases in mean LDL blood levels, as well as decreases in carotid artery intima-media thickness, compared with baseline values. These findings may be explained, in part, by in vitro data, which suggest that MTX may reverse cholesterol transport and may limit foam cell transformation in monocytes and macrophages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of benefit from use of tumor necrosis (TNF)-alpha inhibitors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potentially beneficial effects of TNF-alpha inhibitors on atherosclerotic CVD were noted in a retrospective study of 983 Swedish patients with RA who received a TNF inhibitor when compared with RA patients not treated with one of these drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/19\">",
"       19",
"      </a>",
"      ]. After controlling for age, sex, and disability, the incidence rates of new cardiovascular events for TNF inhibitor treated and untreated patients were 1.4 and 3.5 per 100 patient-years, respectively",
"      <br/>",
"      (adjusted risk ratio of 0.46 [95% CI 0.25-0.85]). However, TNF inhibitors may be harmful to some patients with pre-existing heart failure and should be used with caution in patients with heart failure or decreased left ventricular function; worsening and new-onset heart failure have been reported with these agents.",
"     </li>",
"     <li>",
"      The cardiovascular benefit of the TNF inhibitors may be limited to patients with RA whose synovitis responds to these agents. This was illustrated in a study that used registry data on 10,840 patients with RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/20\">",
"       20",
"      </a>",
"      ]. Rates of myocardial infarction were assessed in 8670 patients treated with TNF inhibitors and 2170 patients treated with traditional nonbiologic DMARDs. Overall, both groups had similar incidence rates of myocardial infarction. However, those patients whose disease activity was reduced by TNF inhibitor therapy within the first six months of treatment had a markedly decreased risk of myocardial infarction (MI) compared with those who continued to have active disease. Myocardial infarction rates per 1000 patient-years were 3.5 and 9.4, respectively (rate ratio 0.36 [95% CI 0.19-0.69]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited observational data suggest that biologic DMARDs do not significantly reduce the risk of hospitalization for cardiovascular events in older patients with RA when compared with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefit of treatment of joint inflammation with disease-modifying antirheumatic drugs (DMARDs), including the TNF inhibitors, is an additional factor that favors aggressive attempts to control synovitis.",
"   </p>",
"   <p>",
"    However, the relationship between chronic inflammation and lipid metabolisms is complex and remains incompletely understood. In patients with RA and suboptimally controlled disease activity, total and low-density cholesterol levels can be lower than in non-RA individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/9\">",
"     9",
"    </a>",
"    ]. Also, biologics targeting proinflammatory cytokines, such as TNF-alpha and interleukin (IL)-6, which can suppress RA inflammation, appear to increase lipid levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT OF ANGINA AND ACUTE CORONARY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical management of patients with RA and with angina",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute coronary syndromes is no different from that in those without RA. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    However, patients with RA who present with acute coronary syndromes may have poorer outcomes than other patients. As an example, in a retrospective study of 40 patients with RA and 40 age- and sex-matched controls, all with acute coronary syndromes, subsequent cardiovascular deaths were significantly more likely in those with RA (40 versus 15 percent) as was the all-cause mortality (47 versus 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to the use of selective COX-2 inhibitors in patients with CVD and interference of some nonselective NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) with the beneficial antiplatelet effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    have been described above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Selective COX-2 inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Low-dose aspirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among those who may require surgery, there are issues unique to patients with RA that must be addressed. These include cervical spine instability and antirheumatic drug management. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15929?source=see_link\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVD is a major contributor to the increased risk of premature death in patients with RA. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H12#H12\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Predictors of CVD mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the acute phase protein responses to inflammation, particularly the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration, may be predictors of the risk of death due to CVD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated the relationship between traditional and nontraditional cardiovascular risk factors and cardiovascular death in a cohort of 603 patients with RA followed for a mean period of 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/24\">",
"       24",
"      </a>",
"      ]. When corrected for other risk factors for CVD death, patients with at least three measurements of sedimentation rates &ge;60",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      were twice more likely to die of CVD than other RA patients (hazard ratio [HR] 2.03, 95% CI 1.45-2.83).",
"     </li>",
"     <li>",
"      A second study of 506 patients with newly diagnosed inflammatory polyarthritis (one-half with RA) found that elevated CRP levels at the time of diagnosis of RA were an independent risk factor for cardiovascular death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/25\">",
"       25",
"      </a>",
"      ]. After adjustment for other risk factors, a CRP level of &ge;5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      was associated with an increased risk of death due to CVD (HR 3.3, 95% CI 1.4-7.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that CRP levels &gt;10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    predict all cause mortality after standardization for traditional risk factors in patients with RA, psoriasis, or ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/26\">",
"     26",
"    </a>",
"    ]. It follows that aggressive DMARD therapy is indicated in patients with active joint inflammation. Another strategy in prevention of CVD in RA as well as the general population is control of periodontal disease, which is independently associated with inflammation and high CRP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/44/31433/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although an elevated CRP level is recognized as a risk factor for CAD in the general population, lower threshold levels are generally used in those without an established diagnosis of an inflammatory disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of CVD on long-term patient outcomes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H12#H12\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite an increased incidence of ischemic cardiac events in patients with RA, the prevalence of clinical angina pectoris in RA patients is lower than in the general population. Aside from this point, the clinical manifestations and diagnosis of CAD are similar in patients with or without RA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with RA &ge;50 years of age, we suggest yearly history, physical examination, and electrocardiogram to periodically assess for the presence of symptomatic CAD or electrocardiographic evidence of a silent myocardial infarction. Exercise or pharmacologic stress testing is suggested for those with symptoms (eg, angina, atypical chest pain, exertional dyspnea) or electrocardiographic findings suggestive of CAD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link\">",
"       \"Screening for coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As in the general population, the differential diagnosis of chest pain in a patient with RA is broad. Some disorders that may be of particular interest are chest wall pain, pericarditis, Herpes zoster, pulmonary hypertension, and thoracic aortic aneurysm or dissection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of atherosclerosis associated with glucocorticoid use may be minimized by using the minimum effective dose of a glucocorticoid for the shortest possible time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H9#H9\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Cardiovascular disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H10#H10\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Lipids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with RA and known CAD who have an average risk of gastroduodenal damage, we suggest use of a nonselective NSAID (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ) rather than a COX-2 selective inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with RA and known CAD who are at increased risk of serious gastroduodenal toxicity (eg, ulcer, bleeding, perforation) and who need an antiinflammatory agent, we suggest use of a nonselective NSAID (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ) and a proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      , etc) rather than a COX-2 selective inhibitor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Selective COX-2 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with RA and CAD who are receiving anticoagulation with a vitamin-K antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) for whom use of a nonselective NSAID is associated with an increased risk of bleeding, we suggest use of the lowest effective dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative to a selective COX-2 inhibitor in this setting is use of the lowest effective dose of a glucocorticoid. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Selective COX-2 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may interact with other antiinflammatory drugs. Nonselective nonaspirin NSAIDs may interfere with the antiplatelet effects of aspirin. When low-dose aspirin and COX-2 selective agents are used together, the incidence of GI events is similar to that of patients treated with a nonselective NSAID. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Low-dose aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the hypothesis has not be adequately tested in a prospective trial, strict control of inflammation due to RA with DMARDs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-TNF therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) may slow the acceleration of cardiovascular risk seen in patients with RA. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Control of inflammation due to RA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Statin therapy reduces cardiovascular risk even in individuals with normal or elevated lipid levels and may have a beneficial effect on markers of inflammation in RA (CRP and ESR). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General prevention issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We agree with the recommendations of the European League Against Rheumatism (EULAR) for cardiovascular risk management in patients with RA. These include aggressive management of traditional risk factors, optimization of antiinflammatory therapy, and the use of a multiplication factor of 1.5 in risk calculations using risk score models in patients with RA who meet at least two of the following three criteria: disease for greater than 10 years, positive testing for anti-CCP antibodies or rheumatoid factor, and the presence of extraarticular manifestations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lipid lowering with statins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H264629617\">",
"       'Our approach to general prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/1\">",
"      Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/2\">",
"      Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/3\">",
"      Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc 2010; 85:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/4\">",
"      Gravallese EM, Corson JM, Coblyn JS, et al. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989; 68:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/5\">",
"      Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/6\">",
"      McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/7\">",
"      Ridker PM, Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum 2009; 60:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/8\">",
"      Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/9\">",
"      Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/10\">",
"      Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/11\">",
"      Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/12\">",
"      Tannenbaum H, Bombardier C, Davis P, et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/13\">",
"      Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/14\">",
"      Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/15\">",
"      Choi HK, Hern&aacute;n MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/16\">",
"      Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/17\">",
"      Georgiadis AN, Voulgari PV, Argyropoulou MI, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008; 38:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/18\">",
"      Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58:3675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/19\">",
"      Jacobsson LT, Turesson C, G&uuml;lfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/20\">",
"      Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/21\">",
"      Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/22\">",
"      Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66:1503.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4371s1-01-FDA-Okada.ppt (Accessed on January 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/24\">",
"      Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/25\">",
"      Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/26\">",
"      Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/44/31433/abstract/27\">",
"      Mochari H, Grbic JT, Mosca L. Usefulness of self-reported periodontal disease to identify individuals with elevated inflammatory markers at risk of cardiovascular disease. Am J Cardiol 2008; 102:1509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7492 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-00EEC62513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31433=[""].join("\n");
var outline_f30_44_31433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY, PATHOGENESIS, AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General prevention issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Limiting glucocorticoid exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lipid lowering with statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264629617\">",
"      - Our approach to general prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nonselective NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Our approach to NSAID use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Control of inflammation due to RA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT OF ANGINA AND ACUTE CORONARY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Predictors of CVD mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15929?source=related_link\">",
"      Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_44_31434="Lichen slcerosus papules and plaques on wrist";
var content_f30_44_31434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58815%7EDERM%2F70580%7EDERM%2F70084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58815%7EDERM%2F70580%7EDERM%2F70084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small, white papules, some coaslescing into a larger plaque, are present on the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small papules are present on the wrist of this patient with extragenital lichen sclerosus. Lesions may closely resemble lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small polygonal papules are present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31434=[""].join("\n");
var outline_f30_44_31434=null;
var title_f30_44_31435="ECG criteria for LBBB";
var content_f30_44_31435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG in LBBB",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        QRS duration",
"       </td>",
"       <td>",
"        &ge;0.12",
"sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Intrinsicoid deflection",
"       </td>",
"       <td>",
"        &gt;0.05 sec in lead V6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"2\">",
"        Common pattern",
"        <br/>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Loss of q wave and wide slurred R in I, aVL, and V6 rS",
"or QS in V1 ST depression and T wave inversion in leftward leads; ST",
"elevation and upright T waves in right precordial leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        These",
"changes reflect relentlessly leftward vectorial forces. V1 morphology",
"depends on initial leftward or rarely rightward forces. ST and T",
"vectors are usually 180&ordm; discordant to the QRS vector.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\" rowspan=\"4\">",
"        Variant pattern",
"        <br/>",
"       </td>",
"       <td>",
"        Terminal S wave in V6 but not usually in I.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean",
"electrical axis superior and to the left (about -55&ordm;).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        ST",
"depression and T wave inversion in leftward leads; ST elevation and",
"upright T waves in right precordial leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        These",
"changes reflect superior and posterior displacement of loop with a",
"terminal, often rightward, conduction delay. ST and T vectors are",
"discordant to the QRS vector.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Major electrocardiographic criteria for left bundle branch block.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31435=[""].join("\n");
var outline_f30_44_31435=null;
var title_f30_44_31436="HFE genotype in HH";
var content_f30_44_31436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HFE genotype in patients with hereditary hemochromatosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Feder, et al",
"      </td>",
"      <td class=\"subtitle1\">",
"       Beutler, et al",
"      </td>",
"      <td class=\"subtitle1\">",
"       Jouanolle, et al",
"      </td>",
"      <td class=\"subtitle1\">",
"       Jazwinska, et al",
"      </td>",
"      <td class=\"subtitle1\">",
"       Carella, et al",
"      </td>",
"      <td class=\"subtitle1\">",
"       Nielsen, et al",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Country",
"      </td>",
"      <td>",
"       USA",
"      </td>",
"      <td>",
"       USA",
"      </td>",
"      <td>",
"       France",
"      </td>",
"      <td>",
"       Australia",
"      </td>",
"      <td>",
"       Italy",
"      </td>",
"      <td>",
"       Germany",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Number of patients",
"      </td>",
"      <td>",
"       178",
"      </td>",
"      <td>",
"       147",
"      </td>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       112*",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       92",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"7\">",
"       Genotype, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        C282Y",
"       </p>",
"       <p>",
"        C282Y",
"       </p>",
"      </td>",
"      <td>",
"       83",
"      </td>",
"      <td>",
"       82",
"      </td>",
"      <td>",
"       91",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       94.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        C282Y",
"       </p>",
"       <p>",
"        H63D",
"       </p>",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       4.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        C282Y",
"       </p>",
"       <p>",
"        Wild type",
"       </p>",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2.7",
"      </td>",
"      <td>",
"       1.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        H63D",
"       </p>",
"       <p>",
"        H63D",
"       </p>",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       1.3",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        H63D",
"       </p>",
"       <p>",
"        Wild type",
"       </p>",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Wild type",
"       </p>",
"       <p>",
"        Wild type",
"       </p>",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All patients had a positive family history of iron overload.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31436=[""].join("\n");
var outline_f30_44_31436=null;
var title_f30_44_31437="Definition metabolic syndrome";
var content_f30_44_31437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five definitions of the metabolic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameters",
"       </td>",
"       <td class=\"subtitle1\">",
"        NCEP ATP3 2005*",
"       </td>",
"       <td class=\"subtitle1\">",
"        IDF 2006",
"       </td>",
"       <td class=\"subtitle1\">",
"        EGIR 1999",
"       </td>",
"       <td class=\"subtitle1\">",
"        WHO 1999",
"       </td>",
"       <td class=\"subtitle1\">",
"        AACE 2003",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Required",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Waist &ge;94 cm (men) or &ge;80 cm (women)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Insulin resistance or fasting hyperinsulinemia in top 25 percent",
"       </td>",
"       <td>",
"        Insulin resistance in top 25 percent",
"        <sup>",
"         &Delta;",
"        </sup>",
"        ; glucose &ge;6.1 mmol/L (110 mg/dL); 2-hour glucose &ge;7.8 mmol/L (140 mg/dL)",
"       </td>",
"       <td>",
"        High risk of insulin resistance",
"        <sup>",
"         &loz;",
"        </sup>",
"        or BMI &ge;25 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        or waist &ge;102 cm (men) or &ge;88 cm (women)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Number of abnormalities",
"       </td>",
"       <td>",
"        &ge;3 of:",
"       </td>",
"       <td>",
"        And &ge;2 of:",
"       </td>",
"       <td>",
"        And &ge;2 of:",
"       </td>",
"       <td>",
"        And &ge;2 of:",
"       </td>",
"       <td>",
"        And &ge;2 of:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        &ge;5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose",
"       </td>",
"       <td>",
"        &ge;5.6 mmol/L (100 mg/dL) or diagnosed diabetes",
"       </td>",
"       <td>",
"        6.1-6.9 mmol/ (110-125 mg/dL)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &ge;6.1 mmol/L (110 mg/dL); &ge;2-hour glucose 7.8 mmol/L (140 mg/dL)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        HDL cholesterol",
"       </td>",
"       <td>",
"        &lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C",
"       </td>",
"       <td>",
"        &lt;1.0 mmol/L (40 mg/dL)",
"       </td>",
"       <td>",
"        &lt;0.9 mmol/L (35 mg/dL) (men); &lt;1.0 mmol/L (40 mg/dL) (women)",
"       </td>",
"       <td>",
"        &lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Triglycerides",
"       </td>",
"       <td>",
"        &ge;1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;1.7 mmol/L (150 mg/dL) or drug treatment for high triglycerides",
"       </td>",
"       <td>",
"        or &ge;2.0 mmol/L (180 mg/dL) or drug treatment for dyslipidemia",
"       </td>",
"       <td>",
"        or &ge;1.7 mmol/L (150 mg/dL)",
"       </td>",
"       <td>",
"        &ge;1.7 mmol/L (150 mg/dL)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Obesity",
"       </td>",
"       <td>",
"        Waist &ge;102 cm (men) or &ge;88 cm (women)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Waist &ge;94 cm (men) or &ge;80 cm (women)",
"       </td>",
"       <td>",
"        Waist/hip ratio &gt;0.9 (men) or &gt;0.85 (women) or BMI &ge;30 kg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        &ge;130/85 mmHg or drug treatment for hypertension",
"       </td>",
"       <td>",
"        &ge;130/85 mmHg or drug treatment for hypertension",
"       </td>",
"       <td>",
"        &ge;140/90 mmHg or drug treatment for hypertension",
"       </td>",
"       <td>",
"        &ge;140/90 mmHg",
"       </td>",
"       <td>",
"        &ge;130/85 mmHg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; EGIR: Group for the Study of Insulin Resistance; WHO: World Health Organization; AACE: American Association of Clinical Endocrinologists; HDL: high density lipoprotein; BMI: body mass index.",
"     <br/>",
"     * Most commonly agreed upon criteria for metabolic syndrome (any three of five risk factors).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     For South Asia and Chinese patients, waist &ge;90 cm (men) or &ge;80 cm (women); for Japanese patients, waist &ge;90 cm (men) or &ge;80 cm (women).",
"     <br/>",
"     &Delta; Insulin resistance measured using insulin clamp.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     High risk of being insulin resistant is indicated by the presence of at least one of the following: diagnosis of CVD, hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease or acanthosis nigricans; family history of type 2 diabetes, hypertension of CVD; history of gestational diabetes or glucose intolerance; nonwhite ethnicity; sedentary lifestyle; BMI 25 kb/m",
"     <sup>",
"      2",
"     </sup>",
"     or waist circumference 94 cm for men and 80 cm for women; and age 40 years.",
"     <br/>",
"     &sect; Treatment with one or more of fibrates or niacin.",
"     <br/>",
"     &yen; In Asian patients, waist &ge;90 cm (men) or &ge;80 cm (women).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640.",
"      </li>",
"      <li>",
"       Meigs James. Metabolic syndrome and the risk for type 2 diabetes. Expert Rev Endocrin Metab 2006; 1:57. Table 1. Updated data from the International Diabetes Federation, 2006. Available at:",
"       <a href=\"file://www.idf.org/webdata/docs/MetS_def_update2006.pdf\" target=\"_blank\">",
"        file://www.idf.org/webdata/docs/MetS_def_update2006.pdf",
"       </a>",
"       .",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31437=[""].join("\n");
var outline_f30_44_31437=null;
var title_f30_44_31438="United States TB case rates (1993 to 2009)";
var content_f30_44_31438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Number of tuberculosis (TB) cases in US-born vs foreign-born persons: United States, 1993-2009*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 384px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Updated as of July 1, 2010.",
"    </div>",
"    <div class=\"reference\">",
"     CDC. Reported Tuberculosis in the United States, 2009. Atlanta, GA: US Department of Health and Human Services, CDC, October 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31438=[""].join("\n");
var outline_f30_44_31438=null;
var title_f30_44_31439="Creation of a cervical esophagostomy";
var content_f30_44_31439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Creation of a cervical esophagostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the portion of the cervical esophagus proximal to the perforation which was dissected for creation of a cervical esophagostomy. The esophagostomy site is located on the anterior chest wall, below the clavicle. A subcutaneous tunnel is made to pass the proximal end of the esophagus to the outside of the chest wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_44_31439=[""].join("\n");
var outline_f30_44_31439=null;
